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This dissertation research examined the influence of a 24-
week walking/jogging program on fasting plasma total cholesterol, 
HDL-cholesterol, glucose, the ratio of HDLC to total cholesterol, 
and body weight. Participants were 11 obese females and 10 obese 
males, 18-30 years of age and 15-40 percent over ideal weight. 
The first 12 weeks consisted of increasing time periods of 
walking and jogging at 65-75 percent maximum effort three times 
per week with a jogging therapist. In the second 12 weeks, sub­
jects ran on their own four times per week. The data collected 
at weeks 0, 4, 8, 12, and 24 included stress test maximum heart 
rate, aerobic capacity, skinfold measurements, height, weight, and 
fasting plasma blood samples (before, after, 20 minutes after test). 
Data from week 24 and the 20-minutes-after test were eliminated 
due to incompleteness. 
Mean body weight loss was nonsignificant for both females 
and males by ANOVA analysis. ANOVA procedures indicated a 
significant (£=0.0367) change in aerobic capacity for females only. 
Inconsistent significant (p < 0.05) associations between blood para­
meter changes and aerobic capacity changes were observed from 
week to week using simple regression. Posttest glucose was 
significantly (£ < 0.05) higher than pretest levels for all time 
periods for both females and males in ANOVA analyses. 
Significant results were limited due to several factors. The 
12-week period was not significant for appropriate physiological 
changes to occur. The subjects' intensity of effort varied in the 
jogging sessions. Also, small sample sizes reduced the power of 
the statistical tests. 
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CHAPTER 1 
INTRODUCTION 
Regular aerobic physical activity provides many benefits to 
the health of the individual. Improved cardiovascular fitness, 
favorable changes in the fasting lipids profile, decreased fasting 
glucose, and weight control are primary goals in the reduction of 
the risk of coronary heart disease (CHD). CHD is a leading cause 
of death in the United States (Gordon, Castelli, Hjortland, Kannel, 
6 Dawber, 1977). Methods of prevention and control of CHD, 
including physical activity, are under intensive investigation. 
Murray, Murray, Murray, and Megan (1978) reported that 
the lack of regular physical activity is a risk factor of CHD. 
Cooper, Pollock, Martin, White, Linnerud, and Jackson (1976) 
found improved levels of physical fitness were associated with 
reduced CHD risk in a cross-sectional study of 3000 men. One 
means by which physical activity may reduce CHD risk is by 
lowering plasma total cholesterol and raising high density lipopro­
tein cholesterol (HDL-C). These blood components are postulated 
to play roles in the development of CHD (Kannel, Castelli, 6 Gordon, 
1979). 
Clinical work demonstrates that physical activity influences 
blood lipid and lipoprotein levels, i.e., total cholesterol and HDL-C, 
as well as glucose (Milesis, 1974; Joseph 5 Bena, 1977; Wood 6 
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Haskel, 1979). Favorable alterations in these blood components may 
ultimately decrease the chance of CHD development. 
The practical implications of using physical activity as a means 
of lowering CHD risk through alterations in blood profiles is a per­
tinent and timely topic of study. Also, the effect of physical activity 
on weight and/or fat loss in obese individuals in relation to blood 
profiles deserves consideration since obesity has also been reported 
to increase one's risk of developing CHD (Gordon et al., 1977). 
This dissertation research examined the influence of the 
24-week jogging program on fasting plasma blood samples' total 
cholesterol, HDL-C, glucose and body weight/fat in a sample of 
obese males and females, 18-30 years of age and 15-40 percent 
over their ideal weight. This ancillary study was part of a larger 
research project, RESHAPE, which evaluated the effects of jogging 
therapy on weight reduction of obese individuals. 
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CHAPTER 2 
REVIEW OF LITERATURE 
The practical implications of using physical activity as a means 
of lowering CHD risk through alterations of blood profiles and body 
weight/fat is a current concern of preventive medicine. The litera­
ture review summarizes research concerning the influence of exercise 
on the blood parameters, body weight, and body composition. Total 
cholesterol is discussed first, followed by HDL-cholesterol, the ratio 
of HDL-C to total cholesterol, and glucose. The last sections review 
body weight and composition changes with exercise and the effects 
of these changes on the blood parameters. 
Total Cholesterol 
Clinical studies have indicated physical activity alters blood 
lipid and lipoprotein levels. Milesis (1974) determined the effects 
of an 11-week physical training program (four weekly, 30-minute, 
walking/running/calisthenics sessions) on serum lipids in 11 male 
subjects compared to 11 male controls 28-54 years of age. A trend 
towards a reduction in serum total cholesterol was seen after 11 weeks. 
The experimental group exhibited a 29.6 mg% greater decrease in 
serum total cholesterol than did the controls. Subjects whose total 
cholesterol levels were relatively high tended to show the greatest 
overall decrease. A significant (£ < 0.05) body fat loss was observed 
in the experimental group while body weight was not appreciably altered. 
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The sum of five skinfolds for the experimental group decreased from a 
mean and standard deviation of 102.3 ± 28 mm to 88.8 ± 27 mm while the 
control group values only changed from 94.4 ± 27 mm to 90 ± 26 mm. 
Fat loss was not significantly correlated with serum total cholesterol 
change, suggesting that the cholesterol reduction was affected by 
other factors. Physical activity itself may play an independent role. 
Lopez-s, Vial, and Arroyave (1974) examined serum lipids and 
lipoprotein changes in 13 medical students (mean age of 22) after 
seven weeks of an exercise regime (four weekly, 30-minute, jogging/ 
biking/calisthenics sessions, 7 METS intensity). A moderate decrease, 
significant at = 0.03, in serum total cholesterol (mean ± SD, 169 ± 
22 to 162 ° 25 mg%) was observed. An earlier study by Vial, Vial, 
Balart, and Lopez-s (1971) with four adult males also observed a 
significant decrease (values not given) in serum total cholesterol at 
the conclusion of a seven-week exercise program (daily, 30-minute, 
running/biking/calisthenics sessions). 
Joseph and Bena (1977) studied an adult active control group 
(already in an exercise class), an experimental group (beginning an 
exercise class for 30 weeks), and an inactive control group. The 
subjects totaled 57 males with an age range of 33 to 62. Training 
heart rates (determined using the Karvonen equation) were main­
tained during the sessions. A significant (£ < 0.01) 18% decrease 
in serum total cholesterol (mean ± SD, 229 ± 54 to 188 ± 36 mg%) was 
observed in the experimental group but no significant changes in the 
control groups were reported (active control : 178± 33 to 180 ± 40 mg%; 
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inactive control: 205± 38 to 208 ± 46 mg%). A significant (£ < 0.025) 
reduction in skinfold thickness in the experimental group was observed 
(mean ± SD, 26 ± 11 to 21 ± 9%) but not in the active control group 
(20 ± 8 to 19 ± 7%). Body weight was not changed which was pro­
bably due to an increase in muscle tissue concomitant with the decrease 
in fat. The authors noted that the active control group might not have 
changed because the study acted as a maintenance program, resulting 
in stable measurements. 
Interpretation and comparison of the results of these studies 
are limited because of variations in the experiments' designs. The 
length of time per exercise period, the number of exercise periods 
per week, the intensity of exercise, and program duration differ 
among studies. These variations in designs exacerbate efforts to 
compare results. Thea mount of exercise necessary to favorably 
alter the risk factors for CHD is currently under investigation. 
Dressendorfer and Gahagen (1979) addressed the issue of 
how much activity is necessary to influence blood lipid levels. Their 
cross-sectional study of 80 male recreational joggers and 64 nonrunner 
controls (ages 22-59) observed lower cholesterol levels (7-26 mg%) in 
the runners than in the nonrunners (jd < 0.05) . No significant 
differences were observed in weight and body fat between groups. 
When compared on the bsais of distance run per week, the high-
mileage group (mean ± SD, 36.2 ± 10 miles per week) was significantly 
(£ < 0.05) less fat (13.6 ± 4%) than the low mileage group (8.6 ± 1 
miles per week, 17.7 ± 7%) but exhibited no significant differences 
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in total cholesterol from the low-mileage group. The authors suggested 
that as little as three miles of jogging per session, three times per 
week, was sufficient to lower serum total cholesterol in a long-term 
exercise program. 
Study designs have not consistently evaluated weight change, 
percent fat change, and diet in relation to the level of physical 
activity. As already indicated, some investigators observed that the 
reductions in serum total cholesterol associated with physical activity 
were independent of body weight and/or percent fat change. However, 
there are contradictory data which indicate that a decrease in fat is 
associated with a decrease in total cholesterol. A ten-week exercise 
study by Campbell (1968) evaluated the effect of exercise (three 
weekly treadmill runs consisting of six alternating five-minute bouts 
with five-minute rests between bouts and a gradual increase from 
5 mph at 0° grade to 7.5 mph at 10° grade on serum total cholesterol 
in 130 college-age males in relation to the morphological constitutions. 
Obese, muscular and slim classifications were used in the experimental 
and control groups. Serum total cholesterol concentrations were 
reduced significantly (jd < 0.05) in the obese active subjects only 
(207 mg% to 195 mg%) , in comparison to the muscular (184 to 181 mg%) 
and slim (177 to 177 mg%) categories. Although a mean weight loss 
of 33 pounds occurred in the obese active students, the decrease in 
serum total cholesterol was independent of alterations in weight and 
diet. Campbell concluded that the serum total cholesterol concentration 
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of individuals of various morphological configurations was influenced 
differently by the exercise program and by changes in configuration. 
Campbell (1965) previously examined the effect of the type 
of exercise upon serum total cholesterol in the 133 college-age males. 
Ten-week programs of various aerobic (i.e. , cross-country running) 
and anaerobic (i.e., weight training) activities were compared. 
Based on the results, total cholesterol concentration was affected 
differently by different types of exercise. Activity of a vigorous 
and dynamic nature resulted in a significant (£ < 0.05) serum total 
cholesterol reduction (180 to 160 mg%), while activity of a vigorous 
but static nature did not affect serum total cholesterol significantly 
(changes in cholesterol ranged from a 7 mg% decrease to a 3.5 mg% 
increase for various activities). The nature of the physical 
activity is an important consideration in the development of a 
therapeutic exercise regime. 
The examination of total cholesterol level changes with exercise 
includes observations of alterations over time periods ranging from 
weeks to years. It may also be of interest to assess the changes 
in total cholesterol levels observed from immediately before to 
immediately after an exercise bout. Since serum total cholesterol 
is not considered a direct energy substrate for physical activity, 
this dimension has been reported in relatively few studies. 
Jirka and Dolezel (1969) reported the influence of one exercise 
session on serum total choolesterol levels in 93 twelve-year-old children. 
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Serum total cholesterol increased after exercise; the rise was signi­
ficantly higher (£ < 0.05) in boys (mean ± SD, 140 ± 15 to 167 ± 23 
mg%) than in girls (146 ± 18 to 157 ± 12 mg%) although at rest choles­
terol levels were significantly higher (£<0.05) in girls. There was 
no relationship between total cholesterol level changes and hematocrit, 
maximal working capacity, working capacity at the pulse rate of 170, 
and maximal oxygen consumption. The serum total cholesterol level 
increase was greater in boys with greater amounts of fat; this 
relationship was not observed in girls. The authors queried whether 
increased estrogen activity in females might be the cause of the 
smaller increase in serum cholesterol after effort. 
Rochelle (1961) compared the mean total cholesterol levels of 
six adults, ages 20 to 38, immediately before and after exercise. 
Preexercise total cholesterol was 192 mg% and postexercise was 
209 mg%. The difference was significant at £ < 0.001. The author 
noted that the increased cholesterol concentrations may have been 
indicative of fat mobilization and use as an ultimate energy source 
in activity. The change in cholesterol level is an interesting obser­
vation which could stimulate further research. 
HDL-cholesterol 
The contribution of serum cholesterol to CHD risk can be 
determined by the cholesterol concentration in various lipoprotein 
fractions. The five major lipoproteins are the chylomicrons, the 
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very-low-density, intermediate-density, low-density, and high-
density lipoproteins. A very large percentage of the total cholesterol 
is carried in the low-density fraction and is considered atherogenic. 
The presence of relatively high cholesterol levels in the high-density 
portion appears protective against CHD (Kannel, Castelli, & Gordon, 
1979). Researchers have concluded that plasma high-density lipo­
protein cholesterol (HDLC) levels are associated with less risk of 
CHD. The plasma concentraiton of HDLC is presently under study 
as an "inverse" risk factor for CHD. 
HDLC is divided into two categories by density range: HDL2 
and HDL3. HDL2 ranges from 1.063 to 1.125 g/ml and HDL3 from 
1.125 to 1.210 g/ml. HDL2 is larger than HDL3, less dense and 
has a higher concentration of cholesterol. Total HDLC is higher 
in women than in men primarily because of a higher concentration 
of HDL2; HDL3 levels are similar (Wood, 1980). Higher HDLC 
levels are also found in long-distance runners and are the conse­
quence of higher concentrations of HDL2 (Wood, Haskell, Stern, 
Lewis, & Perry, 1977). 
Controversy exists about the role of HDLC in CHD risk 
(Forde, Thelle, Miller, 6 Mjos, 1978); however, mounting epi­
demiological evidence supports the association between high HDLC 
and lowered CHD risk (Wood, 1980). HDLC is independent of 
other coronary risk factors in its effects. That is, without changing 
any other variable known to affect this disease state, increasing 
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HDLC appears to lower occurrence rates for CHD in both men and 
women (Gordon, Castelli, Hjortland, Kannel, 5 Dawber, 1977). 
Many longitudinal and cross-sectional studies have indicated 
that regular physical activity increases HDLC. Investigation across 
various age groups of males and females demonstrates lower plasma 
total and LDLC concentrations, and higher HDLC concentrations 
with daily physical activity, i.e., running (Wood Q Haskell, 1979; 
Wood et al. , 1977; Wood, Haskell, Klein, Lewis, Stern, 5 Farquhar, 
1976; Enger, Herbjornsen, Erikssen, 5 Fretland, 1977; Roundy, 
Fisher, 5 Anderson, 1978; Webster, Smith, LaRosa, Meusing, 5 
Wilson, 1978). On the basis of analyses of HDL subfractions in 
seven male runners (ages 42-58) and six female runners (ages 
34-46) in comparison to sedentary controls, the increased HDL level 
was due to a significantly higher HDL2 concentration (male runners 
vs controls: mean ± SD, 115 ± 47 mg% vs 53 ± 44 mg%, £ < 0.005; 
female runners vs controls: 218 ± 79 mg% vs 122 ± 85 mg%, p < 0.05. 
Unchanged HDL3 levels were observed (male runners vs controls: 
259 ± 22 mg% vs 227 ± 45 mg%, £ < 0.05; female runners vs controls; 
220 + 38 mg% vs 220 ± 28 mg%, £ < 0.05 (Krauss, Lingren, Wood, 
Haskell, Albers, and Cheung, 1977). 
Hartung, Foreyt, Mitchell, Vlasek, and Gotto (1978) observed 
significantly higher (no level given) plasma HDLC in 59 male marathon 
runners (65 mg%), and in 85 male joggers averaging 11 miles per 
week (58 mg% compared to HDLC levels in 74 sedentary males 
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44 mg%). It appeared that even males running 11 miles per week 
had significantly higher HDL levels than sedentary men. 
Continuation of this higher activity level maintained this increased 
HDLC level. 
Increases in HDLC concentration and decreases in LDLC 
concentrations have been observed in many longitudinal studies. 
Carlson and Froberg (1967) observed a drop in LDLC from 129 
mg% to 61 mg% at the end of a ten-day 500-km walk in 12 males. 
HDLC increased from 62 mg% to 70 mg% by day six. Altekreuse 
and Wilmore (1973) observed a significant redistribution of plasma 
lipoproteins in 39 sedentary males in ten weeks of a running pro­
gram (averaging five miles per week at 7.5 mph). A study of 22 
obese women (40% fat) engaged in a 17-week jogging program 
(20 minutes twice weekly, 80% maximum heart rate intensity) and, 
following a self-determined calorically restricted diet, demonstrated 
a significant (p < 0.05) increase in the HDL to LDL-cholesterol 
ratio (mean ± SD, 0.38 ± 0.14 to 0.43 ± 0.16) (Lewis, Haskell, 
Wood, Manoogian, Bailey, 6 Pereira, 1976). 
Ratliffe, Elliot, and Rubenstein (1978) observed a significant 
(]3 < 0.05) increase in HDLC in 14 subjects who jogged three times 
per week for 20 weeks at 76% maximum heart rate intensity (mean ± 
SD, 42 ± 10 mg% to 50 ± 10 mg%) as compared to no change in a 
control group (43 ± 12 to 41 ± 9 mg%). The exercise group 
experienced a significant loss (£ < 0.05) in body fat (amount 
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not stated). An inverse relationship was seen between the change 
in HDLC and the change in percent fat. 
In a study of the effects of ten weeks of exercise versus ten 
weeks of exercise plus a weight-loss diet in 35 men (mean age 47) 
and 37 women (mean age 44), a significant decrease (£ < 0.05) in 
total cholesterol and LDLC occurred with or without diet (Weltman, 
Stamford, Levy, Matter, Short, 6 Fulco, 1978). In the male exer­
cise group total cholesterol decreased from 205 mg% to 188 mg%. In 
the male exercise plus diet group, total cholesterol decreased from 
192 mg% to 178 mg%. This total cholesterol decrease was due to a 
decrease in LDLC with a slight increase in HDLC. The LDLC to 
HDLC ratio was significantly reduced (£ < 0.05) in both the male 
exercise group (2.61 to 2.08) and the male exercise plus diet group 
(2.38 to 2.08). Similar results were observed in the females, whose 
HDLC was significantly higher and LDLC to HDLC ratio was signi­
ficantly lower than for the males both pre- and poststudy. 
Erkelens, Albers, Hazzard, Frederick, and Bierman (1978) 
found HDLC increased significantly (4.9 mg%, £ < .001) after one 
week of a three-month exercise program in 18 male myocardial 
infarction survivors. HDLC remained high (total rise of 6.1 mg%, 
p < 0.001) after three months of training. Lopez-s et al. (1974) 
studied the effects of a seven-week exercise program (four 30-minute 
sessions weekly of jogging, biking, and calisthenics, 7 METS) on 
serum lipoproteins in 13 medical students (mean age 22). A 
significant (p < 0.01) rise in HDL was observed (mean ± SD, 
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286 ± 86 to 332 ± 75 mg%), along with significant decreases in VLDL 
(93 ± 57 to 43 ± 41 mg%, £ < 0-01) and LDL (185 ± 57 to 158 ± 39 
mg%, £ = 0. 02). 
The direct association between exercise and an increased HDLC 
was demonstrated in a study of 12 marathon runners (mean age 40) 
who ran ten days (average 28 km/day), rested three days, and 
then ran another eight days (Dressendorfer, Wade, Hornick, 6 
Timmis, 1982). A significant (£ < 0.05) 18% rise in HDLC occurred 
after one week of running. This change was reversed with the 
three-day rest period. HDLC then again rose significantly (£ < 0.05) 
when running resumed (increased 19% on day 17 and 22% on day 20). 
The training distance appeared to be a determinant of HDLC level. 
Results suggested HDLC concentration was related to the amount 
and regularity of exercise training. 
Rotkis, Cote, Coyle, and Wilmore (1980) also observed a 
relationship between HDLC and weekly running mileage. Their 
cross-sectional examination of 109 male subjects indicated HDLC was 
significantly correlated (£ < 0.05) with miles run per week (r=.50) 
and percent body fat (r=-.36). There was a significant increase 
(£ < 0.05) in HDLC across the groups from nonrunners (mean ± SD, 
34 ± 7 mg%) , low-mileage runners (10-19 miles per week, 47 ± 7 mg%), 
intermediate mileage runners (20-39 miles per week, 53 ± 9 mg%), 
to high mileage runners (40 miles per week, 60 ± 9 mg%). This 
association was found independent of body composition, age, and 
diet. 
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Farrell and Barboriak (1980) determined HDLC every two weeks 
in an eight-week running program (70% V02 max, 30-minutes a day, 
3-4 days a week) in 17 formerly sedentary subjects. Participants 
were seven males (mean age 22) and 9 females (mean age 23). An 
insignificant decline in HDLC occurred at two weeks (53.8 to 51.1 
mg%). HDLC increased significantly (£ < 0.05) only at eight weeks 
(51.1 to 57.4 mg%). This occurred in both males and females. 
This change occurred later than the increase in VC^max, indicating 
a lag in HDLC alteration in the exercise program in previously 
sedentary individuals. 
HDLC:Total Cholesterol 
In reviewing past training studies and cross-sectional studies 
of various age groups and sexes, a common pattern of change in 
plasma lipoprotein concentrations is apparent. Work indicates that 
changes which may be desirable can occur in sedentary individuals 
who engage in a regular exercise regime. VLDLC and LDLC concen­
trations can be decreased and HDLC concentrations increased. The 
risk of CHD may be reduced with these changes. 
Contradictions exist in the literature concerning the effect of 
exercise on total cholesterol (Holloszy, Skinner, Toro, 5 Cureton, 
1964). The inconsistencies in total cholesterol change may be 
explained by the fact that this value represents the sum of the 
cholesterol in all the lipoprotein fractions. Alterations occur in 
these fractions in such ways that total cholesterol may or may not 
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reflect them. The HDLC increase and VLDLC and LDLC reductions 
often observed with exercise may cause an increase, decrease, or no 
change in total cholesterol, depending on the extent of these changes. 
The ratio of HDLC to total cholesterol may be the most informa­
tive parameter to examine rather than total cholesterol or HDLC alone 
(Kannel, Castelli, 6 Gordon, 1979). This ratio may provide a better 
indication of CHD risk status because the ratio allows for a relative 
comparison of the variables which seem to have a contrary influence 
upon CHD incidence. The higher the HDLC value, the better the 
ratio. It is of current research interest to recognize and evaluate 
this parameter in conjunction with the use of physical activity for 
weight control and CHD risk therapy. 
Glucose 
Hyperglycemia and impaired glucose tolerance are often observed 
among the obese (Jourdan, Goldbloom, Margen, 6 Bradfield, 1974). 
An increased risk of developing vascular abnormalities may occur 
(O'Sullivan, Cosgrave, 5 McCaughan, 1968). Such changes may lead 
to the development of CHD. Individuals with diabetes have a greater 
risk of CHD. Methods which attempt to improve glucose tolerance and 
decrease fasting blood glucose levels are currently receiving attention. 
Weight loss appears to improve glucose tolerance in obese 
individuals. This effect occurs independently of dietary manipulations 
(Jourdan et al. , 1974), although some controversy exists concerning 
the effects of dietary restrictions on insulin levels (Farrant, Neville, 
8 Stewart, 1969). Physical training decreases insulin response to 
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blood glucose (Quigley, 1979; Lohman, Liebold, Heilman, Senger, 
£r Pohl, 1978). The Lohman et al. study of six runners (mean age 
22, sex not given) demonstrated that while glucose appearance and 
disappearance rates were similar between the athletes and 115 
controls, insulin release was different. The basal insulin level 
of the athletes was 50% lower than that of the controls. This level 
increased 100% after glucose injection in both groups and remained 
constant for three hours in the athletes. However, in the controls 
the initial insulin increase was followed by a further continuous 
increase for an hour (after a 30-minute lag). The authors suggested 
glucose disposal by insulin is more efficient in trained individuals. 
The low insulin response could be due to muscle conditioning, and 
therefore this response could not be generally attributed to a 
diabetic or prediabetic state. Both regular physical activity and 
weight loss may positively affect both glucose tolerance and fasting 
blood glucose levels over time in an exercise program. 
The acute effects of exercise on fasting blood glucose levels 
have also been studied. Serum glucose level rose significantly 
(£ < 0.05) from 96 ± 11 mg% to 170 ± 48 mg% during a single extended 
exercise bout (10 km run) in 13 male athletes, ages 18 to 44 (Lavine, 
Lowenthal, Gellman, Klein, Woedman, 6 Rose, 1977). This increase 
was inversely related to exercise time; that is, the more exertion 
(the shorter the time also), the greater the glucose rise. Some 
evidence has indicated that in short exercise bouts (i.e., 1-20 minutes), 
blood glucose level remains unchanged while muscle glycogen plays a 
major role in energy supply (Keppler, Keul, & Doll, 1969) . 
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The Keppler et al. study of 56 male athletes and 14 students observed 
that a decrease in blood glucose was noted during exercise of longer 
duration. Observations of glucose levels before and after a bout of 
maximum effort (i.e., stress test) would be of interest particularly 
in relation to training effects over time. 
Body Weight and Composition 
References have been made to changes in body fat and body 
weight in relation to blood lipid profiles through the effects of 
exercise programs. Significant changes in body composition can 
result from regular physical activity, and can occur with or without 
dietary changes (Pollock, Wilmore, & Fox, 1978). A large amount of 
weight loss by diet alone may result from lean tissue and water loss, 
rather than fat tissue (Pollock et al. , 1978). Exercise can induce 
hypertrophy of muscle tissue and thus cause a gain in lean body 
weight. Body fat loss can occur simultaneously. Pollock et al. (1978) 
state that little body weight change usually occurs in the first six 
to eight weeks of exercise since fat loss and lean weight gain are 
occurring simultaneously. However, body composition is changing, 
which is a more important indicator of the physical effects of regular 
activity. 
Several studies have demonstrated changes in body composition 
with the adoption of an exercise regime. Carter and Phillips (1969) 
observed a 3-kg decrease in body weight and a 3.8% decrease in fat 
percentage in seven males (mean age 47) who ran 30 minute per session 
two or more times weekly for 26 weeks. Pollock, Cureton, and 
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Greninger (1969) demonstrated a 2.9-kg weight loss and a 1% fat loss 
in 11 males (mean age 32) in a 20-week running program (30 minutes 
per session, 4 days per week). Oscai, Williams, and Hertig (1968) 
observed a 2.4 kg weight loss and a 2.2% fat loss in a 20-week 
running program, 30 minutes per session, 3 times per week, in 14 
males (mean age 37). 
Pollock et al. (1978) noted that comparisons of body composition 
changes in exercise studies are difficult to make because of consider­
able variability in experimental designs. The lack of dietary control 
and quantification of training data exacerbates comparisons. While 
many studies have shown body composition changes with exercise 
as noted earlier, several others have not reported significant 
weight or fat changes (Pollock et al., 1978). 
In their analysis of several studies, Pollock et al. (1978) noted 
that those programs with greater combinations of frequency, dura­
tion, or intensity demonstrated greater change in body composition. 
Eight-to-ten week regimens tended to show only small changes. The 
small changes reflected the lack of sufficient time for full adaptation 
to the exercise to occur, since the first few weeks of training are 
developmental in nature. Carter and Phillips (1969) observed a con­
tinuous body weight and fat loss over a year from the beginning of 
an exercise regime. 
Gwinup (1975) found no weight loss in female subjects until 
walking time exceeded 30 minutes daily. Frequency also appears to 
be important. Pollock et al. (1978) concluded that two-day-a-week 
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programs may not be adequate to cause a significant body fat loss. 
From their review of research, they suggested that for weight and 
fat loss to occur by endurance exercise the following are required: 
(1) 20- to 30-minutes of continuous physical activity; (2) sufficient 
exercise intensity to use approximately 30 kilocalories per session; 
(3) three days per week frequency. Increased frequency, intensity, 
and duration of training should cause greater reductions, total 
energy expenditure being highly related to weight and fat loss. 
Body Composition and Lipids Profile 
The assessment of the relationship between extremes in per­
centage of body fat and serum lipid levels can give an indication 
of the combined risks of a high percentage of body fat and an 
unfavorable lipids profile for CHD. Weltman (1981) examined 69 
females for body composition (hydrostatic weighing), serum total 
cholesterol, and HDLC. Two groups were formed: 48 females with 
40% or more body fat were defined as extremely overfat for the 
study (mean age = 43, mean % fat = 48); 21 females with 35% or lower 
body fat constituted the normal controls (mean age = 40, mean % 
fat = 30). Serum total cholesterol levels were significantly (j) < 0.05) 
higher in the extremely overfat (208 mg%) versus the control females 
(189 mg%). Significantly (£ < 0.05) lower HDLC levels were also 
observed in the overfat (57 mg%) versus the control females (67 mg%). 
A significantly (JD < 0.05) higher total cholesterol to HDLC ratio was 
seen in the overfat (3.6) as compared to the controls (2.8). 
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Extremely overfat females had unfavorable serum lipid profiles. 
An increased CHD risk in overfat females may be due in part to 
a lower HDLC level. Favorable changes in body composition and 
lipids profile through physical activity would be advantageous. 
Favorable changes in lipid levels and body composition were 
demonstrated in a study by Hicks, Morton, Brammel, Johnson, 
Keller, and Mathias (1980) in 19 males, ages 28-64. A 12-week 
exercise program (20 minutes to an hour per session, three times 
per week) resulted in significant decreases in body weight (3.85) 
kg, p = 0.003), body fat (4.6%, p < 0.01), and total cholesterol 
(24 mg%, £ < 0.01). HDLC increased by 5.6 mgi The blood 
values were most affected by the change in body fat. Exercise 
was significantly related to body fat loss which, in turn, had a 
significant effect on blood lipid changes. 
The studies described in this review have provided data con­
cerning specific segments of the population using various designs. 
However, this past research suffers from limitations in design. 
Investigations of the effects of regular aerobic exercise in obese 
females is lacking. The paucity of data available pertaining to 
exercise in obese females makes this an opportune group to 
examine. 
The influence of exercise on the acute changes in blood 
values as well as the chronic alterations merits investigation. A 
more comprehensive evaluation of physiological changes is appropriate. 
Most past research has not included both the acute and chronic 
blood value variations. Also, the frequent monitoring of physio­
logical changes occurring with exercise allows time-controlled 
evaluation of the effects of a program. Most results reported 
have been only pre- and postdata, with no reference to alterations 
in the course of the program. The combination of the positive 
points from past designs with those factors described above would 
provide more comprehensive information for the field. 
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CHAPTER 3 
EXPERIMENTAL DESIGN 
Statement of Purpose 
The research project RESHAPE was designed to evaluate the 
effects of jogging therapy on physiological and psychological para­
meters of obese males and females. This dissertation research 
examined the influence of the 24-week training program upon 
fasting plasma total cholesterol and high density lipoprotein 
cholesterol, as well as fasting plasma glucose levels. Concurrently, 
changes in body weight and skinfold thickness were also measured. 
Frequent evaluations of both the acute and chronic changes in the 
blood values were made. 
Objectives 
The obejctives of this research were to measure changes in 
obese males and females during a 24-week jogging program in 
a) fasting plasma total cholesterol, 
b) fasting plasma high density lipoprotein cholesterol, 
c) the ratio of fasting plasma high density lipoprotein 
to total cholesterol, and 
d) fasting plasma glucose. 
Further objectives were to measure the relative association of fasting 
plasma total cholesterol, high density lipoprotein cholesterol, and 
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glucose with a) relative body weight and b) changes in body weight 
and the sum of four skinfold thickness measures throughout a 24-
week jogging program in obese males and females. A final objec­
tive was to measure changes in fasting plasma levels of total 
cholesterol, high density lipoprotein cholesterol, and glucose 
directly before, after, and twenty minutes after a maximum effort 
exercise bout. 
Hypotheses 
1) A 24-week jogging program has a variable effect on fasting 
plasma total cholesterol in obese males and females. 
2) A 24-week jogging program will increase fasting plasma high-
density lipoprotein cholesterol in obese males and females. 
3) A 24-week jogging program will decrease fasting glucose in 
obese males and females. 
4) The higher the relative body weight in comparison to ideal 
body weight, 
a) the higher the fasting plasma total cholesterol, 
b) the higher the fasting plasma glucose, and 
c) the lower the fasting high-density lipoprotein cholesterol 
in obese males and females. 
5) A decrease in body weight or the sum of four skinfold thick­
ness measures will be accompanied by 
a) a decrease in fasting plasma total cholesterol, 
b) a decrease in fasting plasma glucose, and 
c) an increase in fasting plasma high-density lipoprotein 
cholesterol in obese males and females. 
6) A 24-week jogging program will increase the ratio between 
fasting plasma high-density lipoprotein cholesterol and total 
cholesterol in obese males and females. 
7) Fasting plasma levels of total cholesterol will not vary in 
measurements before, after, and twenty minutes after a 
maximum effort exercise bout in obese males and females. 
8) Fasting plasma levels of high-density lipoprotein cholesterol 
will not vary in measurements before, after, and twenty 
minutes after a maximum effort exercise bout in obese 
males and females. 
9) Fasting plasma levels of glucose will increase from before 
to after measurements and decrease from after to twenty-
minutes after measurements in a maximum effort exercise 
bout in obese males and females. 
Sample Selection and Data Collection 
Through campus advertisements and personal contacts, 39 
volunteers were recruited from the UNC-G student-faculty-staff 
population. Two replicate studies were undertaken, with 20 sub­
jects in the first group and 19 in the second group. The first 
replication began in August 1980 and ended in February 1981. 
The second replication began in January 1981 and finished in 
July 1981. Each replication consisted of a one-on-one contact 
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between each subject and one particular jogging therapist. In the 
second 12 weeks, each participant was expected to run on his or 
her own. Table 1 presents the training program used in the 
study. 
Table 1 
Jogging Therapy Program 
Week 
1-4 
5-8 
9-12 
13-24 
Schedule 
walking-jogging 
with therapist 
walking-jogging 
with therapist 
jogging with therapist 
jogging independently 
Frequency 
3x/week 
3x/week 
3x/week 
4x/week 
Time 
20 minutes 
40 minutes 
60 minutes 
60 minutes 
Each volunteer was interviewed for screening purposes. The 
objectives and design of the study were discussed, a medical history 
was reviewed, consent was obtained, and initial questionnaires were 
administered (discussed below). Requirements for participation 
were as follows: 
1) 18-30 years of age 
2) 15-40% above ideal weight for height, age, and sex 
according to standards set by the Metropolitan Life 
Insurance Comapny (1960) 
3) No known history of angina, high blood pressure, hyper-
lipidemia (above 95th percentile of the Lipid Research 
Clinics Program for triglycerides and blood pressure*) 
and/or overt diabetes 
*(Williams, Heiss, Beaglehole, Dennis, Bazarre, and 
Tyroler, 1980) 
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The trained jogging therapists consisted of graduate students 
and faculty (see Appendix A for training instructions). Each jogging 
session was preceded by stretching and warm-up activities for five 
to ten minutes. Appropriate running techniques were discussed by 
the therapists and subjects. Running style was evaluated by the 
therapists and adjusted according to the subjects' individual needs. 
The first jogging session consisted of 20 minutes of alternate 
walking and jogging at the pace and duration commensurate with 
the participant's level of conditioning. A target training heart 
rate was determined by a maximal effort treadmill test (discussed 
below). Heart rate was monitored by palpation to insure no over-
or underworking. During the program the participants gradually 
increased the jogging time with fewer walking intervals until each 
was able to run continuously during the entire activity period. 
Five to ten minutes of cool-down walking and stretching completed 
the sessions. 
Data were collected at five points in the study: Weeks 0, 4, 
8, 12, and 24. The data obtained were grouped in the following 
categories: 
a) anthropometrics including height (cm) , weight (kg) , 
and four skinfold measurements (tricep, bicep, sub­
scapular , supraileac), 
b) blood pressure, 
c) blood chemistries, 
d) three-day food records, 
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e) treadmill tests, and 
g) psychological questionnaires. 
Blood pressure was determined in the supine position. 
Three blood samples, taken at the time of the treadmill test (before, 
after, and 20 minutes after), were analyzed for total cholesterol, 
HDL-cholesterol, and glucose. Other blood analyses were completed 
by other investigators in the Nutrition Department. Three-day 
food records ware obtained to approximate appetite change. The 
psychological questionnaires included ratings of factors such as 
stress, body image, and depression. 
The treadmill test consisted of a continuous, grade-speed 
incremented exercise bout using the Bruce Protocol (Appendix B). 
The participant walked or ran until reaching maximum fatigue. 
Measurements of heart rate, ventilation, temperature of the expired 
gas, and percentage of oxygen and carbon dioxide in the expired 
gas were obtained at one-minute intervals during the last several 
minutes of the test. Heart rate was determined from electro­
cardiograph recordings obtained by direct leads using a Beckman 
Type R411 Dynograph Recorder during the last ten seconds of each 
minute throughout the test. The highest heart rate measured during 
the test was considered the maximal heart rate. Training heart 
rate range was 65-75% of the maximum heart rate during most of 
the training period. This control of heart rate ensured adequate 
levels of conditioning while not overstressing the participant. 
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Oxygen consumption and carbon dioxide production were 
measured by open-circuit spirometry using the Douglas Bag Method. 
The volume of expired air was measured using a Parkinson-Cowan 
CD-4 dry gas meter previously calibrated using a Tissot gasometer. 
Concentrations of oxygen and carbon dioxide in the expired air 
were determined using the Beckman OM-11 and LB-2 electronic 
gas analyzers, respectively. Gas temperature was obtained from 
a thermistor inserted in the inlet port of the CD-4 gas meter. The 
method described by Consolzaio, Johnson, and Pecora (1963) was 
used to compute 02 uptake and CO2 production. The highest 
rate of 02 consumption obtained during the test was considered 
the maximal 0 2 uptake provided the subject reached an age-
estimated maximum heart rate and R value greater than 1.0. 
Before the treadmill test, 25 ml of blood were drawn from 
the antecubital vein using the vacutainer system (1£", 20 gauge 
needle). Blood samples were taken again immediately after the 
test and twenty minutes later. Hematocrit samples were obtained 
by micropipettes. The blood samples were kept on ice one to two 
hours and then centrifuged (3000 rpm, 20 minutes) and the plasma 
removed. Aliquots for glucose analysis were taken. The remaining 
samples were labeled and frozen for later analysis. Determination 
of glucose, total cholesterol, and HDL-cholesterol (heparin-manganese 
isolation) were made using the Technicon AA II System (Appendix C). 
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Statistical Analyses 
Simple regression was used to assess the effects of changes 
in weight and aerobic capacity (VC^^^nil/kg.min) over time on the 
changes in the blood data. The regression procedure was also 
used to examine the relationship of body composition with the 
relative concentrations of the blood parameters. Sex differences 
and the acute responses to exercise were evaluated using the 
ANOVA procedure. The ANOVA procedure was also used in the 
analysis of the response versus the nonresponse group comparisons 
as discussed in Chapter 4. 
The inclusion of both sexes in this research will add to the 
limited data concerning the effects of physical activity in obese 
females. The consideration of the acute and chronic blood value 
changes in exercise conditioning will provide a more comprehensive 
evaluation of physiological alterations than reported in the past. 
The periodic four-week assessments will allow closer examination 
of the influence of conditioning. The combination of these factors 
in the design will yield valuable information for the field. 
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CHAPTER 4 
RESULTS AND DISCUSSION 
Results 
The results of the first 12 weeks of the jogging therapy 
program for both replications combined are presented in Tables 2 
through 7. The means and standard deviations by sex are presented 
for weeks 0, 4, 8, and 12. Data for subjects who dropped out of 
the study before 12 weeks have been eliminated. For each variable, 
subjects were eliminated if data from two or more periods were 
missing. Reasons for missing data included absenteeism, missing 
blood samples, and inadequate volume of blood for al analyses. 
The data from week 24 and the post exercise data were eliminated 
because the number of subjects having complete data was too small 
to consider in these analyses. All statistically significant data are 
noted as such; other data described are nonsignificant. 
Participation 
A total of 23 females and 16 males were recruited into the 
pilot study; the study consisted of two replications (11 females and 
9 males in the first replication; 12 females and 7 males in the second 
replication). Four of the females and one male were black. All of 
the subjects were between 18-30 years of age and 13-40% over their 
desirable weight according to Metropolitan Life Insurance Standards. 
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None of the subjects had a history of CHD, hypertension, or 
diabetes. The target recruitment goal was a total of 32 subjects 
(16 males and 16 females). Blood data were "complete" as described 
earlier for 11 females and 10 males. 
Table 2 
Drop-Out Rates 
Total 
Dropouts: n Week 0 4 8 12 24 O. "0 Dropouts 
Replication I (11) females 2 3 _ 1 55% 4 
( 9) males - - 1 1 2 44% 4 
Replication n (12) females 2 1 — — 1 33% 4 
( 7) males - - 1 2 - 43% 3 
The dropout rates were similar for both sexes; how­
ever, females were more likely to drop out early in the study (Table 
2). The two female dropouts in the first study (week 1) dropped 
out because of peripheral reasons—e.g. one female dropped out 
because she left school following the heart attack of her father, while 
the other caught the flu and subsequently left school after a two-
week illness. The male who dropped out of the study at eight weeks 
during the first replication had lost 15 pounds and found it was 
easier to run at home by himself (he commuted 40 miles to and 
from school every day). 
Analysis of the Data 
Weight changes and aerobic capacity changes were analyzed 
using ANOVA procedures for comparisons of weeks 0, 4, 8, and 12. 
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The data was also analyzed using ANOVA by the grouping of subjects 
into categories according to weight and VO„ ml/kg.min changes 
Zlfl 3.X 
(aerobic capacity). Two categories were used. A "responder" 
group consisted of those who lost a minimum of 1.4 kg and exhibited 
an increase in V02maxml/kg.min from week 0 to week 12. The "non-
responder" group consisted of all those who lost less than 1.4 kg, 
whether their aerobic capacity increased or not. All subjects fell 
into one or the other of the categories. 
These group comparisons were also used to ascertain if any 
changes occurred in the blood parameters in relation to "response" 
to the jogging program in terms of weight loss and increased aerobic 
capacity. Comparisons of the responders versus the nonresponders 
for blood parameter changes were made. Also, effects of the jogging 
program in terms of weight loss and improved cardiovascular fitness 
via aerobic capacity were ascertained using the relative changes in 
the plasma concentrations of total cholesterol, HDL-cholesterol, the 
ratio of HDL-cholesterol to total cholesterol, and glocuse between weeks 
(weeks 0-4, 4-8, 8-12, and 0-12). Simple regression procedures 
were used with the blood data changes as dependent variables and 
weight and V02rnaxml/kg.min changes as separate independent 
variables. ANOVA analysis were performed to assess sex differences 
and pre- and post exercise differences for the blood data. However, 
these differences could not be corrected for initial sex differences in 
physical condition due to lack of information concerning initial fitness. 
The individual blood data are presented in Appendix D. 
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Body Weight 
The mean body weight (kg) values of both females and males 
at weeks 0, 4, 8, and 12 are presented in Table 3. There was no 
significant change in body weight across time. 
When the females were divided into the responder versus the 
nonresponder groups, the average weight loss of the responder 
group was 6.3 ± 2.7 pounds as compared to 0.97 ±3.9 pounds for 
the nonresponder group from weeks 0 to 12 (Table 4). The mean 
weight changes of the two groups were significantly different 
(£=0.0093). The average weight loss over the twelve weeks for 
the male responder group (8.3 ± 4 pounds) was significantly greater 
(^=0.006) than the weight changes of the nonresponder group (plus 
1.8 ± 4 pounds (Table 5). 
Aerobic Capacity 
Aerobic capacity values for both females and males are pre­
sented in Table 3. Mean aerobic capacity VO„ _ml/kg.min increased 
aIB 3.X 
from 33.9 ± 4.1 to 40.2 ±7.1 for females and from 39.2 ± 4.7 to 44 ± 
4.7 for males. ANOVA for the effect of week was statistically signifi­
cant for females (£=0.0367) but not for males. Scheffe's conservative 
post hoc analysis test showed no significant differences between 
specific weeks. 
The responder group females increased their aerobic capacity 
by a mean of 8.6 ± 0.2 mg/kg.min as compared to 4.6 ± 6.4 ml/kg.min 
for the nonresponder group. The responder group males had a 
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Table 3 
Body Weight and Maximum 
Oxygen Consumption 
(Mean ± standard deviation) 
Females 
Week 0 4 8 12 
Weight, kg a 
(n) 
70±8 
(11) 
70±8 
(11) 
68±7 
(8) 
70±8 
(11) 
'i'02maxml/k8-
(n) 
minb 33.9±4.1 35.9±4.6 32. 5±2.5 40.2±7.1 
(9) (9) (6) (7) 
Males 
Week 0 4 8 12 
Weight, kg 
(n) 
87±12 
(10) 
86±12 
(10) 
85±11 
(10) 
85±12 
(10) 
^°2maxml/kB' min 39.2±4.7 40.9±2.2 42.3±3.3 44.0±4.7 
(n) (9) (8) (8) (8) 
aANOVA not statistically significant for weight. 
^ANOVA statistically significant at p =0.0367 
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Table 4 
Changes in Weight, Maximum Oxygen Consumption, and the 
Blood Parameters for the Female Responder and 
Nonresponder Groups for Weeks 0 and 12 
(Meant standard deviation)3 
Nonresponder 
(n) 
Groups 
Responder 
(n) 
Weight 0.44±1.8 -2. 9±1. 2 
kg (7) (4) 
V02maxml/ke- min 
4.6+6.4 
(5) 
8.6±0.2 
(2) 
Total Cholesterol, -1.3±39 25.8±45 
mg% (7) (4) 
H DL - C hole sterol, 0.6±13 13.3±8 
mg% (7) (3) 
HDL-C :TC -0.02±0.13 0.05±0.01 
(7) C3) 
Glucose, -8.6±10 -5.3±17 
mg% (7) (4) 
Values are expressed as week 12 minus week 0. 
Significantly different at p = 0.0093 in ANOVA analysis. 
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Table 5 
Changes in Weight, Maximum Oxygen Consumption and the 
Blood Parameters for the Male Responder and 
Nonresponder Groups for Weeks 0 and 12 
(Mean ± standard deviation)3 
Nonresponder 
(n) 
Groups 
Responder 
(n) 
Weight, b 
kg 
0.82±1. 8 
(4) 
-38±1. 8 
(6) 
^°2maxml/kS- min 3. 5±4 
(4) 
6. 4±3 
(4) 
Total Cholesterol, 
mg% 
-1. 8±45 
(4) 
32.5+59 
(6) 
H DL - C hole sterol, 
mg% 
8.5±9.1 
(4) 
-0.6±13.1 
(5) 
HDL-C :TC 0.04+0.06 
(4) 
-0.01±0. 09 
(5) 
Glucose, 
mg% 
1.3±17 
(4) 
-3.5±7 
(6) 
Values are expressed as week 12 minus week 0. 
^Significantly different at £= 0.006 in ANOVA analysis. 
37 
greater increase in aerobic capacity of 6.4 ± 3 ml/kg.min as compared 
to the nonresponder group (3.5 ± 4 ml/kg-min). 
Percentage of Fat and the 
Sum of Skinfold Changes 
Adequate data were not available for analysis of the percentage of fat 
and the sum of skinfold changes for the subjects under consideration. 
Questionable validity and reliability of testers and relatively large 
variations in measurements limited the usability of the data. 
Quetelet and the Blood Parameters 
In order to ascertain if a relationship existed between body 
composition and relative blood parameter concentrations, a regres-
2 sion analysis was done using Quetelet values. Quetelet (wt/ht ) 
gives an estimate of body composition and is frequently used in 
surveys (Beal, 1980). No associations were observed between the 
Quetelet index and the relative concentrations of fasting plasma total 
cholesterol, 'HDL-cholesterol, glucose, or the ratio HDL-cholesterol: 
total cholesterol (p > 0. 05). 
Fasting Plasma Total Cholesterol 
Fasting plasma total cholesterol (TC) concentrations are pre­
sented in Table 6. No significant sex differences in TC were 
observed, nor were there any significant differences in pre- and 
postexercise TC concentrations for either sex at any time period. 
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Table 6 
Fasting Plasma Total Cholesterol (mg%) 
(Mean ± standard deviation) 
Females 
Week 0 4 8 12 
Test -
Pre-exercise 192±53 183+51 186±33 201±42 
(n) (11) (11) (8) (11) 
Post-exercise 218±38 192±43 217±53 208±40 
(n) (8) (9) (6) (9) 
Males 
Week 0 4 8 12 
Test 
Pre-exercise 179±43 186±40 196±39 198±47 
(n) (10) (10) (10) (10) 
Post-exercise 206±31 196±32 218±50 205±41 
(n) (9) (9) (10) (10) 
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However, it should be noted fasting plasma preexercise cholesterol 
levels were consistently lower than TC concentrations immediately 
following the termination of each stress test for both males and 
females at all time periods. 
According to a simple regression analysis, a significant 
(£=0.0028) inverse relationship between the change in preexercise 
fasting plasma total cholesterol and the change in VC>2maxml/kg*min 
for weeks 4 to 8 for females was observed. The regression equation 
stated that total cholesterol = -14.78-12.27 V02maxml/kg-min. Pre­
exercise fasting plasma total cholesterol levels for males exhibited a 
significant (£=0.0218) direct relationship with V02maxml/kg*min for 
weeks 4 to 8. The regression equation stated that total cholesterol 
= -5.17+5.5 V02maxml/kg-min. There were no other significant 
changes among weeks for fasting plasma TC levels. 
The mean fasting plasma total cholesterol level decreased 1.3 ± 
3.9 mg% and increased 25.8 ± 45 mg% for the female nonresponder 
and responder groups, respectively, over the 12 weeks (see 
Table 4). In males, the mean fasting plasma total cholesterol level 
increased 32.5 ± 59 mg% for the responder group and decreased 
1.8 ± 45 mg% for the nonresponder group (Table 5). 
Fasting Plasma High-Density Lipoprotein Cholesterol 
Mean fasting HDLC concentrations for females and males for 
weeks 0, 4, 8, and 12 are presented in Table 7. Mean HDLC con­
centrations were significantly different by sex at week 0, preexercise 
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Table 7 
Fasting Plasma High Density Lipoprotein Cholesterol (mg%) 
(Mean ± standard deviation) 
Females 
Week 0 4 8 12 
Test 
Pre-exercise 48±17 48±15 55±16 52±10 
(n) (10) (10) (7) (10) 
Post-exercise 50±14 47+18 57±21 47±8 
(n) (6) (8) (5) (7) 
Males 
Week 0 4 8 12 
Test 
Pre-exercise 34±8 38±9 42±12 37±10 
(n) (9) (8) (7) (9) 
Post-exercise 37±11 39±10 37±9 40±9 
(n) (8) (7) (7) (9) 
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(females: 48 ± 17 mg%, males: 34 ± 8 mg%, £=0.0436). Week 12, 
preexercise values were also significantly different (£=0.0052) 
between females (52 ± 10 mg%) and males (37 ± 10 mg%). Post-
exercise concentrations of HDLC were significantly different 
(£=.0256) at week 8 for females (27 ± 21 mg%) and males (37 ± 9 mg%). 
Pre- and postexercise differences were not significant for either sex. 
A significant (£=0.0492) direct relationship between the change 
in HDLC from week 8 to 12 and the change in weight for males was 
noted by simple regression analysis. The regression equation stated 
that HDLC = 3.22 + 2.14 weight. No significant relationships between 
changes in HDLC concentrations and changes in weight were observed 
for females. There were no other significant changes among weeks 
for fasting plasma HDLC levels. 
Fasting plasma HDLC levels increased only 0.6 ± 13 mg% for 
the female nonresponder group, but increased 13.3 ± 8 mg% for the 
responder group (Table 4). HDLC concentrations decreased 
0.6 ± 3.1 mg% for the male responder group while the nonresponder 
group's HDLC increased 8.5 ± 9.1 mg% over the 12 weeks (Table 5). 
The Ratio of HDLC to Total Cholesterol 
The means and standard deviations for the HDLC to TC ratio 
are presented in Table 8. Sex differences for the ratio were signi­
ficant at week 12, preexercise (females: 0.27 ± 0.07, males: 
0.20 ± 0.07, £=0.0495) and at week 8, postexercise (females: 
0.29 ± 0.11, males: 0.18 ± 0.07, £=0.0464). 
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Table 8 
HDL-Cholesterol: Total Cholesterol 
(Mean ± standard deviation) 
Females 
Week 0 4 8 12 
Test 
Pre-exercise 0.27±0.13 0.27±0.09 0.3110.10 0.27±0.07 
(n) (10) (10) (7) (10) 
Post-exercise 0.25±0.09 0.2810.07 0.2910.11 0.2710.05 
(n) (5) (7) (5) (6) 
Males 
Week 0 4 8 12 
Test 
Pre-exercise 0.1910.06 0.2210.09 0.2210.07 0.2010.07 
(n) (9) (8) (7) (9) 
Post-exercise 0.1810.04 0.2110.06 0.1810.07 0.2110.06 
(n) (8) (7) (9) (9) 
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No significant pre- or postexercise differences were observed 
for either sex within each week. There was no consistent pattern 
of change between mean preexercise HDLC to TC ratios and mean 
postexercise HDLC to TC ratios. The change in the ratio post-
exercise from week 0 to 4 was significant (£=0.0494) in direct rela­
tion to change in V02m ml/kg-min for females. The regression 
equation stated that ratio = -0.05 ± 0.027 V02maxnil/kg-min. A 
significant (£=0.0204) direct relationship was also observed for 
females for postexercise ratio changes from week 4 to 8. The regres­
sion equation stated that ratio = 0.037 + 0.037 V02maxml/kg.min. 
No other significant changes among weeks for the ratio were observed. 
The mean ratio of HDLC to TC decreased 0.02 ± 0.13 for the 
female nonresponder group while it increased 0.05 ± 0.01 for the 
responder group (Table 4) . The male nonresponder group's HDLC 
to TC ratio decreased a mean of 0.04 ± 0.06 while the responder 
group's value decreased a mean of 0.01 ± 0.09. 
Fasting Plasma Glucose 
Fasting plasma glucose concentrations are presented in 
Table 9. Significant sex differences in fasting plasma glucose con­
centrations were observed at week 0, preexercise (females: 93 ± 
17 mg%, males: 100 ± 6 mg%, £=0.0294). Significant differences 
were also observed at week 8, preexercise (females: 90 ± 10 mg%, 
males: 99 ± 8 mg%, £=0.0464) and week 12, preexercise (females: 
86 ± 10 mg%, males: 99 ± 11 mg%, £=0.0117). 
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Table 9 
Fasting Plasma Glucose (mg%) 
(Mean ± standard deviation) 
Females 
Week 0 4 8 12 
Test 
Pre-exercise 93±17 90±6 90±10 86±10 
(n) (11) (11) (8)  (11) 
Post-exercise 121+13 124±14 127±±2 124±19 
(n) (8) (9) (6) (9) 
Males 
Week 0 4 8 12 
Test 
Pre-exercise 100±6 96±8 99±8 99±11 
(n) (10) (10) (10) (10) 
Post-exercise 120±34 124±20 125±21 128±25 
(n) (9) (9) (10) (10) 
Significant pre- and postexercise fasting plasma glucose dif­
ferences were observed for both females and males. For females, 
significant differences (£=0.0001) were noted at weeks 0, 4, 8, and 
12. Postexercise fasting plasma glucose concentrations for females 
for weeks 0 (93 ± 17 mg%) , 4 (90 ± 6 mg%) , 8 (90 ± 10 mg%) , and 
12 (86 ± 10 mg%) were significantly higher than preexercise levels 
for weeks 0, 4, 8, and 12, respectively (121 ± 13 mg%, 124 ± 14 
mg%, 127 ± 13 mg%, 124 ± 19 mg%, respectively). For males, signi­
ficant pre- and postexercise differences for fasting plasma glucose 
levels were observed for week 4 (pre: 96 ± 8 mg%, post: 124 ± 20 mg 
^=0.001), week 8 (pre: 99 ± 11 mg%, post: 128 ± 25 mg%, £=0.0033). 
A significant (£=0.0075) inverse relationship between the 
change in preexercise fasting plasma glucose from weeks 0 to 4 
with the change in V02maxml/kg.min was observed in the females. 
The regression equation stated that glucose = 2.44 -2.7 VO^may 
ml/kg.min. Females also exhibited a significant (£=0.0456) post­
exercise fasting plasma glucose change in direct relation to V02max 
ml/kg-min change from week 8 to 12. The regression equation 
stated that glucose = -9.1 + 1.66 V02maxml/kg.min. There were 
no other significant changes among weeks for fasting plasma glucose. 
Average fasting plasma glucose values decreased 8.6 ± 10.6 
mg% for the female nonresponder group and 5.3 ± 17 mg% for the 
responder group (Table 4). For males, mean fasting plasma glucose 
levels increased for the nonresponder group by 1.3 ± 17 mg% and 
decreased 3.5 ± 7 mg% for the responder group (Table 5). 
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Discussion 
The results of this study are significant in isolated instances. 
No generally consistent pattern of significant changes in the data 
were observed with the jogging program. The inconsistency of the 
fidings makes interpretations difficult. 
The inconsistent significant results of this study were due 
to several factors. The level of conditioning observed in 12 weeks 
may not be enough to invoke changes in body weight, aerobic 
capacity, and the blood parameters examined. Many subjects in 
this study did not run over 30 minutes continuously until weeks 
6 to 8. Also, the intensity of effort by the subjects in the running 
sessions varied considerably. Six weeks of minimal intensity and 
distance could not be expected to provide large physical changes. 
Studies conducted for longer periods of time (i.e., 24 weeks 
up to 24 months) have observed larger decreases in body weight 
and increases in aerobic capacity than were found in this research 
(Dressendorfer 6 Gahagen, 1979; Pollock et al. , 1978). The 
significant ANOVA for aerobic capacity changes in females during 
the program indicated improvement in physical condition with 
exercise from an initially low level. The nonsignificant association 
between Quetelet and the blood parameters merits further 
investigation. The use of hydrostatic weighing would be advisable 
as a more valid indicator of body composition. 
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The jogging program did not result in consistent significant 
changes in the blood parameters for the obese males and females. 
In addition to those factors already described which affected the 
results, the statistical analyses of the blood parameters were limited 
in power due to small sample sizes. When the effects of the program 
were defined by weight loss and increased aerobic capacity, the 
female responder group exhibited some appropriate changes: an 
increase in fasting plasma HDLC and the ratio of HDLC to TC from 
weeks 0 to 12 as compared to virtually no change in fasting plasma 
HDLC and a decrease in the ratio of HDLC to TC for the nonresponder 
females. The male responder group exhibited a decrease in fasting 
plasma glucose as compared to an increase for the responder group. 
The significant associations between changes in aerobic 
capacity and some of the blood parameters in week comparisons 
using regression analysis also suggested that those who responded 
exhibited some appropriate changes. For example, the significant 
inverse association between preexercise fasting plasma glucose 
changes and aerobic capacity changes from weeks 0 to 4 indicates 
a training effect on fasting glucose levels in obese females. The 
significant positive relationship between postexercise fasting plasma 
glucose changes and changes in aerobic capacity from weeks 8 to 12 
for females may reflect a conditioning effect. The direct relation­
ship between mean preexercise HDLC change and weight change 
from weeks 8 to 12 for the males may have been due to increased 
muscle mass with longer running times. This direct association 
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between weight and HDLC is in disagreement with past work (Wood 5 
Haskell, 1979). Examination of endocrinological changes would have 
been of interest. The lack of consistent significant associations 
across time between aerobic capacity changes and blood parameter 
changes limits conclusions. 
The sex differences observed for aerobic capacity, the blood 
parameters, and the responder versus nonresponder groups are 
difficult to interpret. These differences may be due to the original 
differences in the level of conditioning and physical fitness between 
the sexes at the beginning of the study, rather than due to sex per 
se. If adjustments had been possible at the beginning of the study 
to compare the sexes on an equal basis, i.e., correcting for the 
level of fitness, sex comparisons of the blood data would be more 
meaningful. 
The significant pre- and postexercise differences for fasting plasma 
glucose for both sexes illustrate the use of glucose as an energy 
source in the maximum effort stress test. The lack of significant 
changes for either males or females from pre- to postexercise for 
TC and HDLC may suggest that cholesterol is not directly involved 
in energy metabolism during acute periods of maximum exercise. 
The alterations observed from pre- to postexercise may have 
occurred at random. Consideration of changes in free fatty acid 
availability and triglycerides in response to acute bouts of maximum 
exercise stress would be of interest. 
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Future research with larger sample sizes, a longer time period, 
and with better control of intensity of effort in the subjects may 
result in more significant findings than observed here. The data 
currently available support the contention that exercise has positive 
effects on physical condition and obesity. Wood 5 Haskell (1979), 
Lopez-s et al. (1974), Dressendorfer 6 Gahagen (1979) among 
others cited previously have found significant physiological changes 
with regular aerobic activity. Most of this past work has been 
conducted with males. 
Recommendations for future research include the repetition of 
this study with both males and females with greater care and control 
with data collection. A longer time period is essential to observe 
significant physical changes. Careful monitoring of the subjects' 
intensity of effort and progress by the jogging therapists is 
necessary. The use of hydrostatic weighing for body composition 
estimates would be preferable over skinfold measurements. This is 
true particularly with very obese individuals, where the use of skin­
fold calipers may not be possible due to the extreme thickness of the 
fat layer. If possible, more complete blood sampling from subjects 
and thus, increased sample size, would improve the power of statis­
tical tests to detect significant differences. A major limitation was 
the lack of a control group for comparisons with the exercise group. 
The use of controls would help delineate those changes occurring 
due to the exercise conditioning versus random occurrences. 
While the results of this research indicated inconsistent 
significant physical changes with regular aerobic activity, as a pilot 
study it has provided valuable information concerning design and 
data collection. A repetition of this research, with the changes 
suggested, is necessary to more thoroughly evaluate the nature 
and number of the positive results of exercise on improving cardio­
vascular function and thereby decreasing CHD risks associated with 
obesity in males and females. 
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CHAPTER 5 
SUMMARY 
This dissertation research examined the influence of a 
24-week jogging program on fasting plasma total cholesterol, 
fasting plasma high density lipoprotein cholesterol, the ratio of 
high density lipoprotein cholesterol to total cholesterol, fasting 
plasma glucose, and body weight/fat in a sample of obese males and 
females, 18-30 years of age and 15-40 percent over their ideal 
weight. The goal was to determine if a jogging program could 
improve cardiovascular function (as measured by maximal volume 
of oxygen consumed in millileters per kilogram in body weight) and 
favorably alter body weight and composition. Changes in these 
physiological factors were examined in relation to changes in the 
blood parameters. Appropriate alterations in mean TC, HDL-C and 
fasting glucose in obese females and males would improve the risk 
profile of the subjects regarding the development of coronary heart 
disease. 
Thirty-nine volunteers were recruited from the UNC-G student-
faculty-staff population. The first 12-weeks of the. program 
consisted of one-on-one contact between each subject and one parti­
cular trained jogging therapist. In the second twelve weeks, each 
participant was expected to run on his or her own at least 60 
minutes, four times per week. 
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The first four weeks of the program consisted of walking and 
jogging with a therapist for 20 minutes, three times per week. 
Heart rate was monitored and maintained in the range of 65-75% of 
the maximum heart rate as determined in a maximum stress test. 
Weeks 5 through 8 consisted of walking and jogging with the therapist 
for 40 minutes, three times per week. Weeks 9 through 12 consisted 
of 60 minutes of jogging with the therapist three times per week. 
During the second 12 weeks the subject was expected to run 60 
minutes, four times per week, on his or her own. 
Each volunteer was interviewed for screening purposes. All 
subjects had no known history of angina, high blood pressure, hyper-
lipidemia and/or overt diabetes. An initial treadmill stress test was 
administered at week 0. Fasting blood samples were obtained before, 
after, and 20 minutes after exercise. Oxygen consumption was 
determined. Heart rate during the test and the maximum heart rate 
were measured. Prior to the test, supine blood pressure readings 
were obtained. Height, weight, and four skinfold measurements 
(tricep, bicep, subscapular, suprailiac) were determined. These 
measurements were collected again at weeks 4, 8, 12, and 24. 
Fasting blood samples were centrifuged and the plasma removed. 
Glucose analysis was carried out on the fresh plasma. Fasting 
plasma total cholesterol and HDL-cholesterol measurements were 
determined later from frozen samples. The Technicon AA II system 
was used for the plasma analyses. 
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Statistical analyses of the effect of changes in weight and aerobic 
capacity over time on the changes in the blood data consisted of 
simple regression procedures. The regression procedure was also 
used to examine the relationship of body composition (as estimated 
by the Quetelet index) with the relative concentrations of the blood 
parameters. Sex differences and the acute responses to exercise 
were evaluated using ANOVA. 
Data from week 24 and the 20-minutes-after exercise data 
were eliminated because the number of subjects having complete 
data was too small to consider in these analyses. Seven out of 16 
males and eight out of the 23 females dropped out during the 
course of the study. 
Mean body weight losses from weeks 0 through 12 for both 
males and females were nonsignificant. Mean aerobic capacity 
increased for both males and females over the 12 weeks. The 
changes were significant (£=0.0367) for females but not for males. 
The data for sum of skinfold changes and percentage of fat 
estimations were eliminated due to incompleteness, measurement 
problems, and questionable reliability and validity. No significant 
relationships for the association of body composition using the Quetelet 
2 index (weight/height ) with the blood parameters were noted. 
Regression analysis of the relationships between weight and 
VC^j^^ml/kg-min changes with blood value changes over time indi­
cated some significant changes for males and females. For weeks 0 
to 4, females exhibited a significant (£=0.0075) inverse relationship 
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between changes in fasting plasma glucose and aerobic capacity pre-
exercise. There was also a significant (£=0.0494) postexercise 
direct association between the ratio of HDL-cholesterol to total 
cholesterol and aerobic capacity for the females. 
Between weeks 4 and 8 females exhibited a significant (£=0.0228) 
association between mean fasting preexercise plasma total cholesterol 
and aerobic capacity. A significant (£=0.0204) positive correlation 
between the ratio of HDLC to TC and aerobic capacity, postexercise 
was also observed. In this time comparison, males exhibited a signi­
ficant (£=0.0218) positive relationship between fasting plasma total 
cholesterol and aerobic capacity. 
For weeks 8 to 12, a significant (P=0. 0456) positive association 
was observed for females between fasting postexercise plasma glucose 
and aerobic capacity. A significant (£=0.0492) positive relationship 
was noted preexercise between fasting plasma HDL-cholesterol and 
weight for males. 
Significant pre- and postexercise differences in mean fasting 
plasma glucose occurred for both males and females. For females, post­
exercise fasting plasma glucose concentrations were significantly 
(p=0.0001) higher than preexercise values for weeks 0 through 12. 
For males, postexercise levels were significantly higher than pre­
exercise for weeks 4 (p=0.0001), 8(p=0.0014), and 12 (£=0.0033). 
Males and females differed significantly in preexercise fasting 
glucose levels at week 0 (£=0.0294), 8 (p=0.0464), and 12 (£=0.0117). 
The sexes differed significantly in fasting plasma HDL-cholesterol at 
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week 0 (£=0.0436) and week 12 (£=0.0052) pre-exercise and week 8 
(£=0.0256) postexercise. The HDLC to total cholesterol ratio values 
were significantly different between the sexes at week 8, post-
exercise (£=0.0464) and week 12, preexercise (£=0.0495). However, 
the comparisons of the males and females were exacerbated due to 
their unequal starting level of fitness. If adjustments could have 
been made to account for the differences in levels of conditioning, 
the sex comparisons would have been more meaningful. However, 
adjustments were not possible due to the lack of appropriate data 
(fat free weight, etc.). 
Subjects were compared according to a minimum 1.4 kg increase 
in aerobic capacity. The groups were designated as responders 
versus nonresponders. For the females, the responders exhibited 
a greater mean weight change (loss) and higher mean VC^^^ml/kg-
min than that seen in the nonresponder group. Over the 12 
weeks the responder group exhibited an increase in fasting plasma 
total cholesterol along with rises in fasting plasma HDL-cholesterol 
and the ratio of HDLC to total cholesterol. In contrast, the non­
responder females showed a decrease in fasting plasma total choles­
terol, a very small increase in fasting plasma HDL-cholesterol, and 
a decrease in the ratio of HDLC to total cholesterol. Mean fasting 
plasma glucose levels decreased more for the nonresponder females 
than the responder females over the 12 weeks. 
The male responder group had a greater mean weight 
loss and a greater increase in aerobic capacity than the 
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nonresponder group. Fasting plasma total cholesterol increased for 
the responder group and decreased for the nonresponder group. 
The responder group's fasting plasma HDLC levels and ratio decreased 
while those for the nonresponder group increased. For fasting 
plasma glucose, the responder group exhibited a decrease while 
the nonresponder group's concentrations rose over the 12 weeks. 
ANOVA analyses indicated that none of the blood data comparisons 
for these groups were significantly different. 
The significant findings in this study occurred in isolated 
instances. No generally consistent pattern of significant changes 
in the data were observed. The inconsistency of the findings make 
interpretations difficult. 
Several factors affected the results of this investigation. 
The-12 week time period was not sufficient to invoke changes in 
body weight, aerobic capacity, and the blood parameters examined. 
The intensity of effort by the subjects in the running sessions 
varied considerably. Large changes in ph]fsical condition could not 
be expected with these time and degree of intensity limitations. In 
addition to these limiting factors, the statistical analyses of the 
blood parameters were limited in power due to small sample sizes. 
Recommendations for future research include the repetition of 
this study with both females and males, with greater care and con­
trol with data collection. A longer time period is essential for the 
observation of significant physical changes. Careful monitoring of 
the subjects' intensity of effort and progress by the jogging 
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therapists is necessary. The use of hydrostatic weighing is pre­
ferable over skinfold measurements for validity and reliability. 
Accounting for different levels of fitness at the onset of the 
program between the sexes would allow for examination of true sex 
differences in the blood parameters. 
A major limitation of the study was the lack of a control group 
for comparisons with the exercise group. The use of controls would 
help delineate those changes which occur due to the exercise con­
ditioning versus random occurrence. The problem of obtaining 
blood samples needs further consideration; maintaining an adequate 
sample size is a necessity. 
While the results of this research indicated inconsistent signi­
ficant physical changes with regular aerobic activity, as a pilot 
study it has provided valuable information concerning design and 
data collection. A repetition of this research, with the changes 
suggested, is necessary to more thoroughly evaluate the nature 
and number of positive effects of physical conditioning on cardio­
vascular function and CHD risk in obese males and females. 
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GUIDELINES FOR EXERCISE PRESCRIPTION1 
I. Introduction 
This section deals with the prescription of exercise for 
participants entering the beginner's walk/jog program. 
II. Principles of Training 
Certain basic principles of training should be reviewed 
before discussing the actual method of exercise prescription 
for the obese participant. The principles are followed in the 
design of programs and should be understood by the therapists 
facilitating the exercise phases of the rehabilitation program. 
A. Starting Level 
The initial exercise level for the obese client 
should be kept at a low level due to the long decon-
ditioning period that usually preceds entrance into 
the program. This level should be kept low for two 
reasons: 1) The muscles, ligaments, and tendons 
usually require a brief period of adjustment in the 
early stages of a training program to prevent undue 
soreness and minimize orthopedic problems; 2) The 
cardiovascular system of each client is compromised 
by virtue of the fact that they are diagnosed as 
obese and a low-level starter program will allow a 
safe adaptation. 
B. Warm-up and Cool-down 
Every participant should warm up slowly and 
gradually before each exercise session to allow 
adequate circulatory and metabolic adjustment to the 
stimulus phase of the exercise. With warm-up the 
body temperature increases, vasodilation of skeletal 
heart muscle occurs, and the metabolic demands are 
met in this manner. 
After the stimulus phase each participant should 
cool down to allow a gradual return of the metabolic 
and circulatory demand to a safe level. During this 
phase the symptoms of exertion (dyspena, tachycardia) 
should return to normal before the individual leaves 
the program. 
C. Overload and Progression 
In order to produce a training effect the overload 
principle must be applied; ie. , in order for a 
1 Adapted from the guidelines of Bowman-Gray walk-jog program, 
Winston-Salem, NC. 
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physiological adaptation to occur the system must be 
subjected to a workload that is above the level to 
which it is accustomed. The overload, however, must 
be applied in the proper dosage so that it is high 
enough to exceed the threshold, yet low enough to be 
under the safe upper limit of the prescribed range. 
The overload is controlled by the intensity, duration 
and frequency of training. The overload must also 
be applied in a gradually increasing manner, and the 
rate of progression is important. The starter program 
allows for a slow adaptation until the overload can be 
applied at a faster rate. The rate of progression is 
determined by the experience of the individual. If 
the participant is not experiencing any sign of over­
exertion during the program (extreme fatigue, dyspena) 
or overuse (joint, tendon or muscle injury) then the 
rate of progression is safe. The jogging therapist 
should be aware of these signs and symptoms during 
the program. 
D. Specificity of Training 
The change that occurs with specific types of 
training are specific to that training, and specific for 
the target muscle groups. Training for strength will 
not improve endurance, and training for endurance 
will not improve flexibility. Participants are being 
trained for general cardiovascular fitness which will 
be achieved by a program of walking/jogging and 
alternative rainy day methods of aerobic dance, etc. 
Weight loss should occur from an increase energy 
expenditure in conjunction with a modified eating plan. 
III. Exercise Prescription 
The exercise prescription is developed according to set 
criteria that establish the initial load and adjust it for overload. 
These criteria are identified below and the manner in which they 
are used in the prescription is explained. 
A. Type of Activity 
The type of activity prescribed for the participant 
is divided into warm-up activity, aerobics and cool-down 
activity. The warm-up activity consists of stretching 
exercises designed to increase flexibility. 
Stretching (The Runner, September, 1980) 
The therapist should keep in mind that the stretching phase 
be implemented according to the client's individual muscular struc­
ture, flexibility and varying tension levels. The key is regularity 
and relaxation. The object is to reduce muscular tension, 
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thereby promoting freer movements—not to concentrate on 
attaining extreme flexibility which leads to over-exertion. 
A regular stretching program will help to: 
. Reduce muscle tension 
. Improve coordination 
. Increase range of motion 
. Prevent injuries such as muscle strains 
. Decrease perceived exertion in response to stress 
. Develop body awareness 
. Promote circulation 
The easy stretch 
When you begin the stretch spend 10-30 seconds in it. 
Do not bounce. You want a static rather than ballistic movement. 
Go to the point where you feel a mild tension, and try to relax 
as you hold the stretch. The feeling of tension should subside 
as you hold the position. If it does not, ease off until you find 
a level of comfort. The easy stretch reduces muscular tightness 
and readies the tissue for the developmental stretch. 
The developmental stretch 
Move further into your stretch until you feel a mild tension 
and hold for 10-30 seconds. NO BOUNCING. Be in control. The 
tension should diminish. If not, ease off to the point of comfort. 
The developmental stretch fine tunes the muscles and increases 
flexibility. 
1. Pelvic thrust. Stand erect with hands at sides and feet 
spread comfortably apart. Slowly bend the body back, 
while thrusting the pelvic area forward and raising hands 
over head. 
2. Stride. To stretch the muscles at the top of the leg and in 
front of the hips, move one leg forward as shown so that 
the knee of the forward leg is above the ankle of that leg. 
The other knee should be resting on the floor. Lower the 
front of your hip downward to create an easy stretch. 
3. Floor Squat. To stretch the groin area, put the soles of 
your feet together and hold onto your toes. Gently pull 
yourself forward, bending from the hips until you feel the 
stretch in your groin. 
4. Modified V. Extend your legs in a V on the floor. Take 
your right hand down the inside of your right leg, grasp 
the bottom of your foot and extend the right leg into the 
air. Repeat with the left leg. 
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5. Backover. Lie on the floor with arms extended behind your 
head. While exhaling, lift your legs over your head keeping 
them straight until you feel the stretch in your back. DO 
NOT ATTEMPT THIS STRETCH if you have any history of 
back trouble. 
6. Leg Hold. Sit with legs in the extended V position on the 
floor, grasping the lower part of the extended leg with both 
hands. Lean from the hips toward the leg you are holding. 
Repeat with the other leg. 
7. Dance. Stand erect with feet spread wider than shoulder 
width, arm out to the side, the other straight ahead. Bend 
one leg to the side where the arm is straight ahead, keeping 
the other leg extended. Hold and repeat with the reverse 
position. 
8. Leg Pull. Press against a wall with one hand. To stretch 
the quadricops and knee, hold the top of one foot with the 
opposite hand and gently pull your heel toward your buttocks. 
Hold and repeat with the other leg. 
9. Eight Angles. Find a suitable platform about waist high and 
place your leg on it, forming about a 90° angle with your 
other leg. (Lessen the angle if you have difficulty). Face 
straight ahead and slowly bend sideways with your shoulder 
toward the raised knee. Hold. Stand erect and lower body 
toward the knee on the ground. Hold and reverse the 
position. 
10. Wall Push. Lean against a flat surface. One foot should 
be about 18" from wall and the knee bent with the heel flat 
on the ground. The other leg should be extended with the 
heel also being flat. Hold, then switch legs. 
The aerobic activity consists of the walk/jog program. It is 
this phase of the program that is the most important since it 
develops the heart circulatory and muscular systems. Each 
subject will begin jogging therapy by completing a series of 
mini-walks and mini-runs. The purpose of these "mini cycles" 
is to promote enjoyment and a sense of accomplishment, rather 
than pain or muscle soreness. 
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Jogging Therapy Program 
Week Frequency Time 
1-4 Walking-Jogging with therapist 3 x / wk 20 min. 
5-8 Walking-Jogging with therapist 3 x / wk 40 min. 
9-12 Jogging with therapist 3 x / wk 60 min. 
13-24 Jogging independently 4 x / wk 60 min. 
The cool-down activity consists of selected stretching and 
relaxation sessions. 
B. Intensity 
The intensity of effort is the most important criterion to 
control since it represents the level of stress upon the subjects 
cardiovascular system. It is important from both a safety and a 
training viewpoint. Exercise at too high an intensity is not only 
ineffective but it is unsafe, while exercise at too low an intensity 
will fail to elicit a training effect. 
The intensity of effort is prescribed after the graded exer­
cise test and is based upon the heart rate and ECG response 
during the test. The upper safe limit of the heart rate training 
range and the exercise prescription is based upon this value. 
This upper safe limit can be in the form of specific heart rate 
or a specific percent of the functional capacity. 
Functional Capacity 
The range of heart rate is used to determine the various 
percentages of functional capacity rather than the maximal heart 
rate. The percentages of heart rate range correlate more closely 
with the actual percentages of the metabolic capacity (percent 
^°2 max or maximal oxygen uptake) than the percent of maximal 
heart rate, i.e., it is more representative of the actual work 
being done. 
Percentages of functional capacity are determined as follows: 
HR max = 100% = = 180 beats/min 
90% - 169 
Upper limit = 85% = 163. 5 
80% = 158 
70% = 147 
Threshold = 60% = 136 
50% = 125 
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HR rest 
40% 
30% 
20% 
10% 
0% 
114 
103 
92 
81 
70 beats/min 
This computation method is used to determine the recommended 
heart rate range for training for each participant after each graded 
exercise test. Since each person differs in HR max and HR rest, 
each individual will have his own heart rate range for training. 
In the early stages of training, the clients are instructed to 
stay within the 30 to 60 percent range as a starter program. After 
he/she has progressed with no complications; has learned to correctly 
count pulse rate; and recognizes his/her limitations, the 60 percent 
level can be exceeded. The participant should then operate within 
the training zone of 60-85%. 
American College of Sports Medicine, Guidelines for Graded Exercise 
Tasting and Exercise Prescription: Lea and Felinger, 1975. 
American Heart Association, Exercise Testing and Training of Indivi­
duals with Heart Disease or at High Risk for its Development: 
A Handbook for physicians, New York: American Heart 
Association, 1975. 
Amsterdam, E. A., J. H. Wilmore and A. N. DeMaria (eds.) 
Exercise in Cardiovascular Health and Disease, New York: 
Yorke Medical Books, 1977. 
Cooper, Ken H. Aerobics. New York: Bantam Books, 1977. 
Katch, Krank I., McArdley, William D. Nutrition, Weight Control 
and Exercise. Boston: Houghton Mifflin Co., 1977. 
. Breathing 
. Clothing 
. Creative Visualization 
. Relaxation 
. How to monitor Heart Rate 
. Aerobics 
Recommended Readings 
Tips: To be Included 
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When the obese lose weight they may be disillusioned when 
they find that most of their difficulties—mainly mental—still persist. 
Run, before eating: With the body at rest, the energy needs 
are primarily in the internal organs, the heart, the digestive system, 
etc. About 80% of the blood supply goes to these organs, and 20% 
goes to the inactive skeletal muscles. But as you move into action 
the blood starts shifting to service these muscles with energy until, 
at maximum exertion, a complete shift has occurred with about 80% 
of the blood (and O2) going to the muscles. 
After exercise, it takes some time (an hour or more) for the 
blood to shift back again. Thus, the internal organs during this 
period are not being serviced maximally. In layman's language, the 
digestive system is then in no mood to take on a lot of food. 
APPENDIX B 
Treadmill Testing Procedures 
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Outline of Test Procedure: Rosenthal Laboratory, University of 
North Carolina at Greensboro. 
I. Pre-Test Procedure 
A. Subject Preparation 
1. anthropometric measures, fasting blood sample 
2. apply electrodes 
3. 5-min rest — record RHR and BP 
B. Warm-up 
II. Test Procedure 
A. Administer Bruce Tm Protocol 
B. Record HR each minute 
C. Collect expired air at 2-minute intervals 
D. Collect blood sample at end of test 
III. Post-Test Procedures 
A. Analyze expired air for FEO2, FECO2, volume, temperature 
B. Record BP 
C. Take blood sample after 20 minutes' rest 
Position (5) Needed for Each Test—Review of Responsibilities 
1. EKG (1 person) 
a. apply electrodes carefully 
b. check transmission 
c. record HR, transfer data 
d. remove electrodes 
e. clean-up 
2. Treadmill (1 person) 
a. set clock and treatmill 
b. review procedures with subject 
c. run test, help record data for gas analysis 
3. Spotter (1 person) 
a. administer any anthropometric tests, 24 hr history 
b. stand behind subject throughout warm-up and test 
c. put on headgear and noseclip and remove them. 
d. help subject on and off Tm 
e. clean headgear 
4. Gas Collection and Analysis (2 people) 
a. check bags, analyzer, data sheet (record collection times) 
b. prepare headgear, mouthpiece, noseclip 
c. analyze content of bags 
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Treadmill Operator 
The following responsibilities are assigned to the treadmill 
operator: 
1. Upon arrival in lab, check Tm setting. Be sure both speed 
and grade are functioning properly. If not, check connection 
with Tm. 
2. Briefly remind subject of procedure for getting on and off Tm. 
3. Begin warm-up by saying something like: 
" (name) , " we'll begin your warm-up. You'll 
be walking at " Then after the subject is comfortable 
go over stress test procedure. Remind subject of hand 
signals. 
4. After warm-up, set beginning test speed and grade. 
5. Watch subject for any signs of distress. 
6. Be alert to time framework for changing speed and grade. 
7. Stop test immediately if difficulties arise. Otherwise, ask 
subject for hand signal again to be sure of his/her fatigue 
level. 
8. After test, reset Tm to warm-up speed and grade. 
Treadmill Protocol: Bruce Protocol 
Aftdr 5-minute warm-up at mph and % grade, 
subject will rest briefly while headgear and mouthpiece are adjusted. 
The test will begin at 1.7 mph and 0% grade. The speed and grade 
will increase after each 3 minute period until maximal volitional fatigue. 
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EKG Recording: 
Heart rate will be recorded by direct lead during the last 
10-second period of each minute. Only record 10-12 "peaks." 
Label each recording with the workload and time (i.e., min 4, 
2.5 mph, 2^% grade). Immediately upon completion of the test 
mark 7 R waves and distance between these in mm. Look up 
corresponding HR (b/min) from chart and circle. This procedure 
allows for a check system. After having a "check," record data 
on data sheet. 
Gas Collection and Analysis 
1. Upon arrival in lab, evacuate all bags and close valves. 
2. Set up headgear, mouthpiece, noseclip, towels. 
3. Check analyzers, drierite, telethermometer. 
4. Record subject's name, weight, height along with date, T° lab, 
barometric pressure, name of test. 
5. Rotate valves connected to bags at the exact time indicated. 
will involve either 1-min or 2-min sampling procedures. 
6. After test completion, analyze contents of all bags according to 
procedures described in "dry" run 
a) take 30 sec. sample for O2 and CO2 
b) push expired air through CD-4 and record volume 
c) record temperature of the gas 
*Be sure time of gas collection is written in space provided above 
results. 
APPENDIX C 
Determination Methods for Total Cholesterol, High 
Density Lipoprotein Cholesterol, 
and Glucose 
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MICRO 
Industrial Method 1)339-26 
A/IV/a/3 
CHOLESTEROL (DIRECT) 
(Range: 10-500 mg/dl) 
HISTORY 
The Technicon cholesterol (direct) method is based on the work of Levine, Morgenstern, 
and Vlastelical who automated the manual cholesterol method of Huang, Chen, Wefler, 
and Raftery.2 
The reaction of cholesterol with strong acids was first described by Liebermann^ in 
1885 and developed by Burchard^1 in 1890. In the classical Liebermann-Burchard 
reaction, concentrated sulfuric acid is added to a solution of cholesterol and 
acetic anhydride. During the ensuing reaction, several color changes are observed 
in the reaction mixture. The initial red color changes to violet and finally to 
green at the completion of the reaction. 
The main problems in developing a practical cholesterol method based on the Liebermann-
Burchard reaction were the instability of the acid reagent and the instability of the 
final product. In 1961, Huang et al formulated a stable Liebermann-Burchard reagent. 
This fornultion consisted of the following: 
Glacial acetic acid 300 ml 
Acetic anhydride 600 ml 
Sulfuric acid 100 ml 
Sodium sulfate, anhydrous 20 g 
It was recommended that this stable reagent be mixed with the unknown cholesterol 
sample and that the mixture be allowed to stand at room temperature for 20 minutes; 
after which time, the absorbance of the reaction mixture was determined spectro-
photometrically at either 550 nm or 610 nm. 
After evaluating the cholesterol method of Huang et al, Ness, Pastewka, and Peacock^ 
suggested that the cholesterol be added to a chilled (0°C) color reagent and then 
be allowed to slowly reach room temperature. It was reported that by controlling 
the reaction in this manner, broad and nonspecific absorption curves were prevented. 
Subsequent automation of the method by Levine et al introduced several other modifica­
tions: The formulation of the cholesterol color reagent was modified to prolong pump 
tube life; the cholesterol color reagent was chilled as suggested by Ness et al; and 
the absorbance of the analytical stream was measured at 630 nm, to minimize the effect 
of serum pigments. 
SPECIAL MERITS ANP LIMITATIONS 
The automated cholesterol method allows r.ipid and precise determination of cholesterol 
in serum. It is limited, however, by the large number of substances known to inter­
fere with it. In this regard, refer .to tl.a paragraph in this method titled 
"Interfering Substances." 
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EXPLANATION OF METHOD 
Aa illustrated in Che flow diagram, the prediluted serum sample is mixed with an air-
segmented stream of cholesterol color reagent. During the ensuing reaction of 
cholesterol with Liebermann-Burchard reagent, the color of the reaction mixture 
changes from red, to violet, and finally to green. The following mechanism has 
been proposed^ for this reaction: 
(1) Cholesterol + H2SO4 bis-cholescadienyl monosulfonic acid 
(2) bis-cholestadienyl monosulfonic acid + H2SO4 
bis-cholestadienyl disulfonic acid 
The absorbance of the analytical stream is measured at 630 no In a flowcell that has 
a 15-mm light path and an inside diameter of 1»5 mm. 
REAGENTS 
GENERAL INSTRUCTIONS 
1. The technologist must adhere strictly to all warning and precaution statements 
specified within this Section. Refer to the specific reagent container label 
for the product expiration date and for pertinent storage information. 
2. All reagents, whether supplied by Technicon in a ready-for-use form or prepared 
by the technologist must be free of particulates and other foreign oacter, 
and must not exhibit any obvious color changes. EACH REAGENT SHOULD BE EXAMINED 
THOROUGHLY BEFORE USE. Reagents displaying any signs of instability should be 
replaced. 
CHOLESTEROL COLOR REAGENT (Technicon Product No. T21-0901)*(Must be prepared by the user) 
Corpos it ion: 
Part A (Technicon Product No. T01-0883) 1 bottle 
Part B (Technicon Froduct No. T01-0890) 1 bottle 
Preparation Instructions: 
The two-part Cholesterol Color Reagent must be prepared for use as follows: 
1. Obtain one bottle of Part A and one bottle of Part B. 
-WARNING'. -
THE FOLLOWING WARNING APPLIES TO THE CONTENTS OF PART A, 
PART B, AND THE MIXTURE PRODUCED BY COMBINING PARTS A AND B. 
THE TECHNOLOGIST MUST MAINTAIN A CONSTANT AWARENESS OF THE 
CORROSIVE NATURE OF THESE REAGENTS. WHILE PERFORMING THE 
PREPARATION PROCEDURE, EXERCISE EXTREME CARE TO PREVENT 
REAGENT SPILLS. WHILE IT IS ALWAYS CONSIDERED GOOD LABORATORY 
PRACTICE TO WEAR PROTECTIVE GLASSES, THE TECHNOLOGIST SHOULD 
CONSIDER IT MANDATORY WHILE HANDLING THESE REAGENTS. 
-DANGER!-
CAUSES SEVERE BURNS. VAPOR HARMFUL. COMBUSTIBLE. DO NOT 
GET IN EYES, ON SKIN OR CLOTHING. DO NOT BREATHE VAPOR. 
* «r^il3jle °"ly 3S 3 kit' lndividual components (Part A or Part B) cannot be 
ordered separately. 
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-POISON-
(CALL, A PHYSICIAN) 
FIRST AID 
Affected eyes: Irrigate thoroughly with water. In severe cases or 
where splashing occurred, obtain medical attention. 
Skin contact: Drench with water. Remove contaminated clothing 
and wash before reuse. 
Vapor inhaled: Remove from exposure, rest, and keep warm. Give 
drinks to relieve throat irritation. 
If swallowed: Wash out mouth thoroughly with water. Give plenty 
of water to drink followed by milk of magnesia. Obtain medical 
attention. 
2. Prior to combining Part A and Part B, chill both parts to approximately 
4°C. Technicon recommends that the two bottles (Part A and Part B) be 
stored in a refrigerator overnight prior to use. 
3. Open the two bottles (Part A and Part B). Retain the cap from the bottle 
containing Part B. 
U. Carefully pour the contents of the bottle containing Part A into the bottle 
containing Part B. 
NOTE: When Parts A and B are combined, a slight temperature rise will result. 
This temperature rise is not detrimental to the product. 
5. Tightly replace the cap on the bottle containing the mixture of Parts A 
and B (working reagent), and invert the bottle three times under a hood. 
6. Remove the cap from the bottle, and place the bottle in the system refrigerator. 
If the system is not equipped with a refrigerator, store the working reagent 
in an Ice bath. 
IMPORTANT: The temperature of the working reagent must be kept at approximately 
4°C prior to and during use. 
7. Connect the appropriate reagent line. 
STABILITY 
When handled and stored as directed, the working reagent and its component parts 
are stable for the periods of time indicated below: 
Part A (Technicon Product No. T01-0883) - One year at room temperature* 
Part B (Technicon Product No. T01-0890) - One year at room temperature 
Working Reagent (Parts A and B combined) - One month when stored at 4°C 
IMPORTANT: Tightly cap the bottle of working reagent during storage. This will 
prevent the reagent from possibly absorbing moisture from the atmosphere. 
* During storage, Part A may show signs of slight discoloration (yellow). This 
discoloration within limits, does not affect the usefulness of the reagent. 
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WETTING AGENTS 
REAGENTS 
Cholesterol Color Reagent (Liebermann-Burchard) 
TECHNICON 
NO. 
prepared 
by user 
WETTING 
AGENT 
None 
Required 
INSTRUCTION 
REAGENT CONSUMPTION' DATA 
Reagent consumption data are provided to assist the technologist in determining 
his particular reagent requirements. By multiplying the reagent flow rates (ml/min 
or ml/h) provided in Table 1 by the anticipated average instrument operating time, 
the technologist can project reagent preparation and reordering schedules. 
Table 1. - REAGENT FLOW RATES 
REAGENT 
FLOW RATE 
al/min ml/h 
1.6 96.0 "Cholesterol Color Reagent" (must be prepared by user) 
SAMPLE DILUTION 
Serum specimens with cholesterol concentrations greater than 500 mg/dl should be 
diluted with distilled water or saline (0.9% NaCl) and reassayed. 
INTERFERING SUBSTANCES 
A number of substances have been reported to cause physiological changes in serum 
cholesterol concentrations.8.9 ,10,11 \ comprehensive list of these substances, their 
serum concentrations, and their possible physiological involvements is beyond the scope 
of this method. 
Several substances and conditions have been reported to interfere with the cholesterol 
(direct) method and, if present in the serum reagents, or system, may interfere in 
the manner described: 
Amphotericin 
Bilirubin 
Example: 
Hemolysis^ • 
Lipemia^ 
Llpochrome^ 
Tryptophan^ 
Large concentrations (1 mmol/llter) of amphotericin B have 
been reported to cause elevated serum cholesterol values. 
Empirical data derived from the addition of known amounts of 
bilirubin to serum indicate that for each mg/dl of bilirubin 
present in the serum sample, an absorbance equivalent to 
approximately A mg/dl of cholesterol occurs. 
A serum containing 5 mg/dl bilirubin will give a 20 mg/dl 
positive error for cholesterol. If the bilirubin level is 
known, the correction can be readily made. 
Hemolysis has been reported to cause elevated serum cholesterol 
values. 
Llpemia" has been reported to cause turbidity in nonextraction 
cholesterol methods, thus elevating the cholesterol values. 
Lipochrome has an appreciable absorbance at 630 nm and can 
be detected as cholesterol, thus causing an apparent increase 
in cholesterol concentration values. 
Tryptophan has been reported to elevate cholesterol values. 
CIlOl.nSTEROL - SHA MICRO 
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SAMPLE INTERACTION STUDY 
Experimental evidence has indicated that within the expected range of values for 
the cholesterol method, the amount of sample interaction (carryover) is not 
clinically significant (less than 52). In the extreme case where a sample with an 
extremely high concentration is followed by a sample with a very low concentration, 
the amount of sample interaction may result in a clincially significant (greater 
than 57,) elevation of the low-value sample. In routine clinical use, this situation 
is seldom encountered. 
The quantitative effect of carryover at any concentration level is directly related 
to the operating condition of the systen. Conditions such as worn pump tubes, a 
dirty flowcell, etc., will have a deleterious effect on results. Accordingly, 
the user is urged to adhere strictly to the maintenance recommendations prescribed in 
the system operation manual . 
METHOD PERFORMANCE CHARACTERISTICS 
Sensitivity at 500 mg/dl 
Coefficient of Variation at 195 mg/dl 
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TROUBLESHOOTING 
For troubleshooting purposes, note the following information for the cholesterol 
(direct) method: 
SMA AAII 
1. SMA Reference Serum (200 mg/dl) Abaorbance -
2. Full Scale (500 mg/dl) Absorbance -
NOTE: The absorbances (E) specified are approximate. Minor variations in reagent 
pump tubes, flowcells, etc., may cause deviations from the specified values. 
Acceptable ranges should be determined for each system over a period of time. 
Table 2 provides a list of possible trouble that could be encountered while running 
the cholesterol (direct) method. The Table also lists the causes of each difficulty 
and corrective maintenance procedures: 
-WARNING-
THE TECHNOLOGIST MUST MAINTAIN AN AWARENESS OF THE CORROSIVE 
NATURE OF THE CHOLESTEROL COLOR REAGENT. "WHILE PERFORMING THE 
FOLLOWING TROUBLESHOOTING PROCEDURES, EXERCISE EXTREME CARE TO 
PREVENT REAGENT SPILLS ON LABORATORY PERSONNEL AND EQUIPMENT. 
WHILE IT IS ALWAYS CONSIDERED GOOD LABORATORY PRACTICE TO WEAR 
PROTECTIVE CLASSES, THE TECHNOLOGIST SHOULD CONSIDER IT MANDATORY 
WHILE TROUBLESHOOTING THE CHOLESTEROL METHOD. REFER TO THE PARA­
GRAPH TITLED "REAGENT," FOR A COMPLETE DESCRIPTION OF THE FIRST 
AID TO BE APPLIED IN THE EVENT AN ACCIDENT DOES OCCUR. 
Table 2 - TROUBLESHOOTING 
TROUBLE PROBABLE CAUSE CORRECTIVE MAINTENANCE NOTE 
No reaction Sample c pull-through line 
clogged Of pinched 
Change tubing, and clean out 
ail nipples with a fine wire 
probe. 
Pump platen SHCUt.Q NOT be 
removed before the channel u 
pumped dry. If removed, there 
be a back flow of reagent 
into the sample line when red-
gent is left m channel. 
|w AIMING || 
REAGENT LEFT IN THE 
TUBING IS A POTENTIAL 
PERSONAL HAZARD AND 
ALSO CAN RESULT IN A 
RAPID DEGRADATION 
OF THE PUMP TUBES. 
Defective reagent Change reagent. Prepared reagent must 
be refrigerated. 
High results Bilirubin interference Sobc.ct bilirubin inter-
1«ie* 
For each mg/dl of bil irubin there 
w»U ft* « '. » '-" 'dl incf»«*'.-' •• • ' 
Table 2 - TROUBLESHOOTING (Continued) 
TROUBLE PROBABLE CAUSE CORRECTIVE MAINTENANCE NOTE 
Noise, poor 
curver (lost 
Oefective cholesterol color 
reagent 
Prepare fresh reagenc 
' 
Of w«ih| 
Lois of intersample bubble Change debubbler l ine. Check (or presence of inter-
sample bubbles at debubbler. 
Check bubble integrity at N13 
nipple. 
Check bubble integrity at con* 
nections between polyethylene 
tubing and glassware. 
Precipitate in platinum 
nipple 
The precipitate can be caused 
by an imbalance between 
reagent and the sample. The 
system should be cleaned with 
1 N NaOH. Flush with air, then 
with \  N NaOH. again with air. 
then with 0.25 N HCl 
solution, and finish with air. 
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HDL ISOLATION FROM PLASMA 
Derived from: Albers, J.J., G. R. Warnick, and M.C. Chenng. 
Quantitation of High Density Lipoproteins. Lipids 
13 (12) : 926, 1978. 
Principle: The non-HDL apo-B associated lipoproteins are 
selectively precipitated from plasma by sulfated polysaccharides 
(heparin) and divalent cations (Mn+2), leaving HDL in 
suspension. 
Reagents: 
1. Manganese Chloride Solution 1.06M: (MnC^.4H„)-MW=197.91) 
Weigh out 209. 78g MnCl^.H^ and dissolve in a small amount 
of distilled water. Dilute to 1 liter volume with distilled water. 
This solution is thought to be stable indefinitely. 
2. Sodium Chloride-0.15M (saline): Weigh out 8.77g NaCl and 
dissolve in about 500 ml distilled water. Bring up to 1 liter 
volume with distilled water. 
3. Heparin-40,000 units/ml: Commercial heparin preparations 
contain different strengths of heparin by weight (units per 
mg) . CHECK LABEL ON HEPARIN VIAL BEFORE PREPARATION 
If heparin preparation contains 140 units/mg, weigh out . 286g 
heparin and dissolve in 1 ml .15 M saline. Since the volume 
is so slight, use a very small glass vial to prepare solution. 
The heparin is hard to dissolve so it will be necessary to 
vortex the solution vigorously. Before removing an aliquot 
for the combined reagent, let the heparin solution set awhile 
and check to make sure all the heparin is in solution. ; 
Prepare fresh for each run. 
4. Combined heparin-manganese reagent: Add .6 ml 40,000 units 
heparin/ml to 10 ml 1.06 M MnC^^HgO. Prepare fresh for 
each run. 
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PROCEDURE: 
1. Remove plasma samples from refrigerator and allow to warm to 
room temperature. 
2. Mix plasma samples well. Using a calibrated Oxford Macro-
pipet (or volumetric pipet), transfer 2 ml plasma into 12 or 
15 ml glass conical centrifuge tubes. Run duplicates. 
3. Vortex combined heparin-manganese reagent well. Using a 
calibrated Oxford or SMI Micropipet, transfer .2 ml combined 
reagent into each centrifuge tube. A precipitate will form 
immediately. 
4. Vortex each tube lightly and cover with plastic wrap or 
Parafilm. 
5. Allow the tubes to stand at room temperature for 10 minutes. 
6. Centrifuge tubes in the refrigerated centrifuge for 30 minutes. 
A hard pellet will form on the bottom of the tube. 
NOTE: It is necessary to use a swinging bucket rotor for 
this procedure in order to form a pellet which is lodged in 
the bottom of the conical centrifuge tube. If a fixed-angle 
rotor is used, like those on the Sorvall, a firm pellet will 
not form and the precipitate will smear along the sides of 
the tube. 
7. Supernatants may be directly decanted, but to avoid possible 
contamination, remove most of the supernatant with a Pasteur 
pipet and store in a 7 ml or larger vial. 
8. HDL are suspended in the supernatant. Cholesterol and 
triglyceride determinations are run directly on the super­
natant following isopropanol extraction; i.e., treat super­
natant like unfractionated plasma. 
9. Prepare standard solutions of 20, 50 and 100 mg/dl with 
appropriate dilutions of the test set standards for making 
the standard curve. Analyze each standard in duplicate 
with each run. 
Final concentrations: 
2+ 
92mM Mn , 1.47 mg heparin/ml, 205.8 units heparin/ml 
A constant amount of cholesterol in the supernatant has been 
measured over a heparin concentration range of 92-734 units/ml 
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(Ishikawa, T. T. et al., Lipids 11(8): 628, 1976) and 1.2 - 2.0 mg/ml 
(Warnick, G. R. et al., J. Lipid Res. 19: 65, 1978). A final Mn 
concentration of 92mM has been shown to be more ideal for HDL 
precipitation from plasma than the commonly used concentration of 
46mM (Albers et al., Lipids 13: 926, 1978). 
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TECHNICON METHOD No. SE4 003GFJ4 DATE RELEASED: SEPTEMBER 1974 
GLUCOSE (GLUCOSEOXIDASE) 
HISTORY 
The forerunner of the present Technicon glucose method, 
introduced in 195G by Keston,' determined glucosc in 
biolog-cal fluids hy a glucose-peroxidase enzymatic 
procedure. Teller et al, in 1856, were the first to apply tins 
procedure to serum jnd plasma.7 
o-dianisidme, o-anisulme, o-toluidine. and indophenol have 
since been used as 0 ;  acceptors for the en.-ymatic reaction, 
but ihvst; chfomogt;m wn»» colloidal and unstable.'1 
Difficulty also had been encountered in the direct 
application of these itMgents to scrum or plasma because of 
the piesence nf inhibitors, such as ascorbic acid, unc and. 
bilirubin, catachols, glutahione, and cysteine or because of 
hemolysis. These compounds inhibited the deteiminatmn 
by competing with the chromogcn as proton donors/ 
In the past decade, sermautomated and completely 
automated glucose mrihods have been pi uposod while ihe 
search for a specifu; enzym;i:ic procedure for measuring the 
glucose concentration in broloy.ral fluids continued A 
sem (automated deteimin.ition requiring ,j manual 
protein frrr fi ltrate and the use of ferncyanide as the redo* 
indicator was described by Tucker and Hall.4 This method 
likewise was limited by interferences from the reducing 
substances previously mentioned, lammes and Nordschow 
d"--clly measured lb-- hydrogen perioxtd*' which is 
pii •d'.ir» d as a tei.r«ai y complex with titanium and xylenol 
ot.inf|r- Serum vv»s rorummended 'or use m this procedure 
di:>- to negative inti-iferenccs by common anticoagulants 
and anJ'glycolytic agents. A semiautomated procedure for 
unnary glucose util ising the fluoromeiiic 
he>.ok inj^e'glucosi' R phosphate dehydrogenase NADP 
rea- tio^ was described by Scherstein and Tibbling.6 
Excellent adaptation of Calhiochcm's hexokmase procedure 
to the Tcchmcon AutoAnalyzer II continuous-flqw 
analytical instrument was reported by Widdowson and 
Penton' and by Ncei"yh, even though the method proved 
expensive for rauii ' i" use 
The Technicon glucose oxidase method is a modification of 
the procedure of Gor.hman and Schmit*.9 In this 
colorimetric determination for glucose, the specificity of 
glucose oxidase is combined with a new peroxidase 
indicator couple, 3 methyl 2 benzothiaolinone hydrozone 
(MBTH) and dimethylnniline (DMA). Glucose oxidase 
initiates the following reactions which generates hydrogen 
peroxidase that reacts with the peroxidase indicator to 
form an intensely-colored indamine dye. 
(1) Glucose + Oj * H; 0 ^ lu^osp«. Gluconic Acid + H2 03 
Oxidase 1 2 
(2) MBTH + DMA + H j O j  Peroxidase tndamine Dye + 
^ Hj 0 « OH 
MERITS AND LIMITATIONS 
The glucosc (glucnse-oxidase) method provides rapid and 
precise ISD 0.8-1 C1 '  97 mg/dl glucose} results. The method 
correlates well with the manual hexokinase method 
(bias — 2.05 mg/dl) and the automated o-toluidine method 
(bias<0 I mg/dl) Comparison studies performed with the 
Technicon SMA 12/60 multichannel biochemical analyzer 
indicate no significant difference between the two systems 
for the sample population. The glucose (glucose-oxidase) 
method was compared also to a neocuproine method. The 
results indicated a bias, with the glucose oxidase method 
giving approximately 5 'o lower values for the sample 
population. Refer to "Interfering Substances" for a dis­
cussion of those substances that may interfere with this 
method. 
EXPLANATION OF THE METHOD 
The glucose method combines the specificity of a glucose 
oxidase reaction with a peroxidase indicator reaction. In 
the presence of peroxidase, 3-methyl-2-benzothiazolinone 
hydrazone oxidatively couples with N, /V-dimethylamline to 
form a stable, intensely colored, water-soluble indamine 
dye. 
Except where noted, the performance data for thi, method were 
obtained using instruments, reagents, calibrators, standards, and 
controls manufactured by the Technicon Instruments Corporation. 
TECHNICON INSTRUMENTS CORPORATION/TARRYTOWN, N.Y. 10591 
O0i*9«4/1»)-I.1ESP y 
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SAMPLER IV 
To Want 
SAMPLING RATE - 60 SAMPLES/h 
SAMPLE-TO WASH RATIO - 9:1 
20 Turni 
157-BO0»O1 
PN 170-
0120-12 
SAMPLER WASH SOLUTION DISTILLED 
WATER 
DlALYZER HEATING BLK/BLK (0.32) 
10 Turni 
157-0251-01 SOOIUM CHLORIDE. 0 9% 
Q BLU/BLU (1.601 Q WITH BRIJ35 
ORN GRN 0.10 SAMPLE 3 PATH 5.37 ml 
177- B004-02 BLK/BLK <0 3?) QAm 
GLUCOSE OXIDASE (WORKINGI 
157 B273 01 
170-0427-01 
TYPE C 
MEMBRANE BLU/BLU (1.60) 
"77- B004 01 WORKING 
MBTH/DMA REAGENT ORN/WHT (0.23 
PEROXIDASE (WORKING) ORN/WHT (Q.23) 
FROM F/C PULL-THROUGH ARM BLU/BLU (1.60) To W«ite 
GLUCOSE 
To Watte 
NOTE 
MODULAR RECORDER 
DIGITAL 
PRINTER* 
20 Tumi 
157 0246 01 THE NUMBERS WITHIN PARENTHESES 
SIGNIFY FLOW RATES IN ML/MIN. 
COLORIMETER 
INTERFERENCE 
FILTER - 600 nm 
FLOWCELL 
LENGTH. 15 mm 
ID: 1.5 mm 
• Only used when ModuKit Digital Printer is not used 
•• Reler 10 "Preoj'dtton Pioccttu«es" lo* Mu<lu'.v Digital Pnm«i 
control teitinqi 
Figure 1 GLUCOSE (GLUCOSE OXIDASE) FLOW DIAGRAM 
As illustrated in Figure 1. a direct sample is diluted with 
glucose sample diluent, mixed, and dialy?ed into a buttered 
glucose oxidase reagent The solution »s intubated in a 
37.5 °C heatmg hath to allow the enzymatic reaction to 
take place. 
A solution of 3 methvl-2 boiwothiazolinone hydrazone arid 
dimethylaiiihne (MBTH.-DMA) is added tu and mixed with 
a recipient stream containing H20 :. Peroxidase reagent is 
added and mixed with the indicator (H :  0 :) solution. The 
peroxidase coupling ol MBTH and DMA forms the soluble 
tndamme dye. The amount of dye formed is proportional 
to the amount of glucose present in the original sample. 
The color reaction takes place at room temperature. The 
stable blue color of the reuction product is measured at 
600 nm in a flowcell that has a 15 mm light path and an 
insidi* (liametei of 1.5 mm. 
EQUIPMENT 
The equipment required to perform this method is the 
Tochmco'i AutoAn,ily?rT II continuous-flow analytical 
instrument for th;> drtoimunition of glucos<? 
In'.'COS' OK'd.ise) in srium 
The following modules and accessories comprise the 
Technicon AutoAnalyzer tl system that is used to perform 
glucose {glucoseoxidase) determinations: 
1. Sampler IV with macroprobe 
2. Cam 60/Hr, 9:1 (used on systems not equipped wuh or 
not operated with a Modular Digital Printer) 
3. Proportioning Pump III 
A. Glucose (Glucoje-Oxidase) Manifold No. l7Q-AQ81*fi1 
5. Single-Channel Colorimeter witn a 1,5-mm x i5*mm 
flowcell and two 600-nm interference filters. 
6. Modular Digital printer 
7. Technicon AutoAnalyzer II Recorder (chart 
speed—1 inch/minute) 
REAGENTS 
The reagents used in this procedure should be free of 
particulates and other foreign matter, or obvious color 
changes. EACH REAGENT SHOULD BE EXAMINED 
THOROUGHLY BEFORE USE. Reagents displaying any 
signs of contamination, instability, or color change should 
be replaced. Refer to the specific reagent container label for 
the product expiration data and for pertinent storage 
information. 
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Sodium Chloride 0.9%, with Brij-35 (Tcchnicon Product 
No. T01-0381) 
Glucose Oxidate (Working) (must be prepared by the user) 
Glucose Oxidase Reagent Diluent (Technicon Product No. 
T21-0588) 
Composition 
Glucose Oxidase (Reconstituted) 
Glucose Oxidase Reagent Diluent 
(Technicon Product No. T21-0588) 
Brij-35*, 30% Solution 
(Technicon Product No. T2V0110) 
1 ml 
OS 100 ml 
NOTE 
This diluent is used m the preparation of the glucose 
oxidase reagent (working). 
Brij-35, 30% Solution (Technicon Product No. T21-0110) 
0.1 ml 
(2 drops) NOTE 
Preparation Instructions 
Place 1 ml of glucose oxidase (reconstituted) in a 100-ml 
volumetric flask. Dilute to volume U00 ml) with Glucose 
Oxidase Reagent Diluent (Technicon Product No. 
T21 0588), and mix. Add 0.1 ml (2 drops) of Brij-35, 30% 
Solution {Technicon Product No. T21-0110). and mix. 
'Storage Instructions 
Store the glucose oxid.ne (working) roncy'iil in a refrigerator 
at a temperature between 4 C and 6 ''C. 
Stability 
When prepared and stored as directed, the glucose oxidase 
(working) reagent is stable for 48 hours. 
Glucose Oxidase (Reconstituted) (must he prepared by 
the user) 
Composition 
Glucose Oxidase 1000 U/ml 
(Technicon Product No. T1 *1-0578) when renin 
stituled .is 
directed 
Distilled water 25 ml 
Preparation Instructions 
Reconstitute the lyophilizcd glucose oxidjse by accuratcly 
pipetting 25 ml of distilled water into the vial containing 
the prodjet. Swirl the vial gently until the contents arc 
completely dissolved. 
Storage Instructions 
Store the glucose oxidase (reconstituted) leagent at a 
temperature between 2 and 8 °C, 
Stability 
When prepared and stored as directed, this reagent is stable 
for one month. 
Glucose Oxidase (Technicon Product No. T11-0578) 
| NOTF 
This lyophili?ed product is used to prepare 
the glucose nxid.ise (reconstituted) redgent. 
The Brij-35, 30% Solution is used in the 
preparation of the glucose oxidase (working) 
reagent. 
CAUTION! 
MAY BE HARMFUL IF SWALLOWED 
MAY CAUSE EYE IRRITATION 
MBTH/DMA Working Reagent (must b« prepared by the 
user) 
Composition 
Stock MBTH 2.0 ml 
Stock DMA 3.0 ml 
MBTH/DMA Working Reagent Diluent 
(Technicon Product No. T21-0577) 5.0 ml 
Distilled Water OS 100 ml 
DANGER! 
MAY BE FATAL IF 
ABSORBED THROUGH SKIN 
CAUSES EYE BURNS 
HARMFUL IF INHALED 
Avoid contact with eyes and skirl. 
Do not breathe vapor. 
Wash thoroughly after handling. 
- POISON -
(CALL A PHYSICIAN.) 
FIRST AID 
Skin contact: Drench with water, and wash 
thoroughly with soap and water. Remove 
•nd wash contaminated clothing befora 
reuse. If contamination has been other than 
slight, obtain msdical attention. 
Affected eyes: Irrigate thoroughly with 
water, and obtain medical attention. 
Vapor inhaled: Remove from exposure, 
rest, and keep warm. In severe cases, obtain 
medical attention. ' 
If (wallowed: Wash out mouth thoroughly 
with water, and obtain medical attention. 
o« ICt Am»fici Int . Wilmington, Del. 
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Preparation Instructions 
WARNING 
DO NOT PIPETTE THE MBTH OR DMA 
BY MOUTH. 
Pipette 2.0 ml of stock MDTH, 3.0 ml of DMA, and 5.0 nil 
of MBTH/DMA Working Reagent Diluent (Technicon 
Product No. T210577) into a 100-ml volumetric flask 
containing approximately 50 ml of distilled water. Dilute tc 
volume (100 ml) with distilled water, and mix thoroughly. 
Storage Instructions 
The reagent must be stored at room temperature in a amber 
glass bottle. 
Stability 
When prepared and stored as directed, the reagent is stable 
for 24 hours. 
Stock MBTH (must be prepared by the user) 
MBTH (3*Methvl-2*Ben2othtazolinone Hydrazont 
Hydrochloride) (Technicon Proouci wo. Tl i-uti75) 
| NOTE 
The MBTH is used in the preparation of the 
stock MBTH reagent. 
WARNING! 
HARMFUL IF SWALLOWED 
MAY CAUSE EYE OR SKIN IRRITATION 
Wash thoroughly after handling. 
Avoid contact with skin end eyes. 
MBTH/DMA Stock Reagent Diluent (Technicon Product 
No. T21 0574) 
| NOTE | 
The MBTH/OMA stock reagent diluent is 
used in the preparation of the stock MBTH • 
reagent. 
NOTE 
The stock MBTH is used in the preparation 
of the MBT H/DMA working reagent. 
Composition 
MBTH (3-Methyl'2-Ben*othid2olinon«; 
Hydrazone Hvrtrochioriaej (lemmcon 
Product No Til -U575) 1 v,a' 
MBTH/DMA Stock Reagent Diluent 
(Technicon Pioduct No. T21 -057-1) OS 100 ml 
WARNING! 
HARMFUL IF SWALLOWED 
MAY CAUSE EYE OR SKIN IRRITATION 
Wash thoroughly after handling 
Avoid contact with skin and eyes. 
Pn-fjjfjtion instructions 
WARNING 
DO NOT PIPETTE MBTH BY MOUTH. 
Empty one vial of MBTH (Technicon Product No, T11-
0575) into a 100-m! volumetric flask containing about 
50 ml of MBTH/DMA stock reagent diluent, and mix 
until the MBTH is dissolved. Dilute to volume with 
MBTH, DMA stock reagent diluent. 
Storjcjc Instructions 
The u'jgent must tjf stored at room temperature in an 
jniU-i gL.is bottl". 
Sutb t : . : y  
Wlv i |)M'p<ncd .i 'd ^ duectcd, th»> reagent is st.it)!'' 
fOl two vvei'ks. 
CAUTION! 
MAY BE HARMFUL IF SWALLOWED 
MAY CAUSE EYE IRRITATION 
Stock DMA (must be prepared by the uter} 
NOTE 
The stock DMA is used in the preparation of 
the MBTH/DMA working reagent. 
Composition 
HMA (Technicon Product No. T21-0576) 1.0 ml 
MB I H/DMA Stock Reagent Diluent 
(Technicon Product No. T21-0574), 100 ml 
DANGER! 
MAY BE FATAL IF 
ABSORBED THROUGH SKIN 
CAUSES EYE BURNS 
HARMFUL IF INHALED 
Avoid contact with eyes and skin. 
Do not breathe vapor. 
Wash thoroughly after handling. 
- POISON -
(CALL A PHYSICIAN.) 
FIRST AID 
Skin contact: Drench with water, and wash 
thoroughly with soap and water. Remove 
and wash contaminated clothing before 
reuse, if contamination has been other than 
slight, obtain medical attention. 
Affected eyes: Irrigate thoroughly with 
water, and obtain medical attention. 
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Vapor inhaled: Remove from exposure, 
resi, and keep warm. In severe cases, obtain 
medical attention. 
If swallowed: Wash out mouth thoroughly 
with water, and obtain medical attention. 
Preparation Instructions 
WARNING I 
^SBBSBBSSEBBBSi 
DO NOT PIPETTE DMA BY MOUTH. 
Pipette 1.0 ml of DMA (Technicon Product No. T21-0576) 
into a 100 ml volumetric flask. Add 75 ml of MBTH/DMA 
Stock Reagent Diluent (Technicon Pioduct No. T21-0574), 
and mi* by shak-ng. Dilute to volume (100 ml) using the 
MBTH/DMA stock reagent diluent. 
Storarji.' Instructions 
Sji'U' the stock DM.?\ rp,if|«»nt at room temperature in an 
amhor glass bottle, 
Stab i l i t y  
VVhen p«ep,ired and sio'ed as directed, the DMA stock 
reagent is stable loi two weeks. 
DMA iDimethvianihne) (Technicon Product No. T21-0576) 
NOTE 
The DMA is used in the preparation of the 
stuck DMA reagent. 
DANGER! 
MAY BE FATAL IF 
ABSORBED THROUGH SKIN 
CAUSES EYE BURNS 
HARMFUL IF INHALED 
Avoid contact with eyes and skin. 
Do not breathe vapor. 
Wash thoroughly after handling. 
- POISON -
(CALL A PHYSICIAN.) 
FIRST AID 
Skin contact: Drench with water, and wash 
thoroughly with soap and water. Remove 
and wash contaminated clothing before 
reuse. If contamination has been other than 
slight, obtain medical attention. 
Affected eyes: Irrigate thoroughly with 
water, and obtain medical attention. 
Vapor inhaled: Remove from exposure, 
rest, and keep warm. In severe cases, obtain 
medical attention. 
If swallowed: Wash out mouth thoroughly 
with water, and obtain medical attention. 
MBTH/DMA Stock Reagent Diluent (Ttchnicon Product 
No. T21-0574) 
| NOTE | 
The MBTH/DMA stock reagent diluent is 
used in the preparation of the stock DMA 
reagent.' 
CAUTION! 
MAY BE HARMFUL IF SWALLOWED 
MAY CAUSE EYE IRRITATION 
MBTH/DMA Working Reagent Diluent (Ttchnicon Product 
No. T21-0577) 
| NOTE | 
The MBTH/DMA working reagent diluent is 
used in the preparation of the MBTH/DMA . 
working reagent. 
DANGER! 
CAUSES SEVERE BURNS 
VAPOR HARMFUL 
COMBUSTIBLE 
Do not get in eyes, or on skin or clothing. 
Do not breathe vapor. 
- POISON -
(CALL A PHYSICIAN.) 
FIRST AID 
Affected eyes: Irrigate thoroughly 
with water. In severe cases or where 
splashing has occurred, obtain medical 
attention. 
Skin contact: Drench with water. 
Remove contaminated clothing and 
wash before reuse. 
Vapor inhaled: Remove from 
exposure, rest, and keep warm. Give 
soothing drinks to relieve throat 
irritation. 
If swallowed: Wash out mouth 
thoroughly with water. Give plenty of 
water to drink followed by milk of 
magnesia. Obtain medical attention. 
Peroxidase (Working) (must be prepared by the user) 
Composition 
Peroxidase (Technicon Product 
No. T11 0579) 1 vial 
Peroxidase Reagent Diluent 
ITechnicon Pioouct No. T21-0582) QS 200 ml 
Preparation Instructions 
1. Ftll the vial of Peroxidase (Technicon Product No. 
T1V0579) to about 3/4 o1 »ts volume with Peroxidase 
Reagent Diluent {Technicon Produci No. T21-0582). 
2. Mix to dissolve the contents, then transfer into a 200 ml 
volumetric flask. 
3. Rinse the vial three times as described in steps 1 and 2. 
4. Dilute to volume with Peroxidase Reagent Diluent 
(Technicon Product No. T21-0582). 
5. Mix gently to prevent foaming. Transfer to an amber 
glass bottle. 
Storage Instructions 
Store the peroxidase (working) reagent in a refiigerator at a 
temperature beiween 4 "C to 6 °C. 
Stability 
When prepared and stored as directed, the peroxidase 
(working) reagent is stable for one week. 
Peroxidase (Technicon Product No. T11 0579) 
NOTE 
The peroxidase is used in the preparation of 
the peroxidase (working) reagent. 
Peroxidase Reagent Diluent (Technicon Product No. 
T21 0582) 
| NOTE"" 
The peroxidase reagent diluent is used in the 
preparation of the peroxidase reagent. 
REAGENT CONSUMPTION DATA 
The reagent consumption data listed in Table 1 are 
provided to assist the technologist in determining his 
particular reagent requirements. By multiplying the 
applicable reagent flow rate (ml/min or ml/h) by the 
anticipated average instrument operating time, the 
technologist can project reagent "preparation and 
reordering schedules. 
Table 1 REAGENT FLOW RATES 
FLOW RATE 
REAGENT ml/min ml/h 
Sodium Chloride, 0.9% with Brij-35 
(Technicon Product No. T01 -0381) 1.60 96.0 
Glucose Oxidase (Working) 
Reagent (must be prepared 
by the user) 1.60 96.0 
MBTH/DMA Working Reagent 
(must be prepared by the user) 0.23 13.8 
Peroxidase (Working) Reagent 
(must be piepared by the user) 0.23 13,8 
CALIBRATION REFERENCE 
(Refer to Table 2.) 
Technicon SMA Reference Serum 2 w/Diluent 
Table 2 AVAILABLE TECHNICON SMA REFERENCE SERUM 2 PRODUCTS 
PART NUMBER PRODUCT NAME UNIT OF SALE 
Ttr-WSD-56 
T03-8025-57 
SMA Reference Serum 2 and SMA 
Reference Serum 2 Diluent 
SMA Reference Serum 2 and SMA 
Reference Serum 2 Diluent 
6 sets x 50 ml 
7 sets x 25 ml 
T03-8150-56 
T03 B125 57 
SMA Reference Serum 2 CPK and 
SMA Reference Serum 2 Diluent 
SMA Reference Serum 2 CPK and 
SMA Reference Serum 2 Diluent 
6 sets x 50 mi 
7 sets x 25 ml 
T03-8250-56 
T03-8225-57 
SMA^Reference Serum 2 SGPT and 
SMA Reference Serum 2 Diluent 
SMA Reference Serum 2 SGPT and 
SMA Reference Serum 2 Diluent 
6 sets x 50 ml 
7 sets x 25 ml 
Composition Technicon SMA Reference Serum 2. — 
Technicon SMA Reference Serum 2 is a lyophilized product 
that has been formulated for use as a general-purpose 
reference material for calibrating Technicon 
AutoAnalyzer II systems. This reference material is 
prepared from defibrinated human plasma to which various 
constituents have been added to achieve specific 
concentration levels. Added enzymes are derived from the 
following sources: LDH - bovine heart muscle, GOT -
porcine heart muscle, alkaline phosphatase — chicken 
intestine, GPT — porcine heart muscle. Other additives are 
included to improve and preserve the characteristics of the 
product. 
A complete description of SMA Reference Serum 2 
together with suggested procedures for confirming its 
constituent concentrations are provided in Technical 
Bulletin No. TT3-0313-20. A copy of this bulletin is 
provided in VOLUME III of the Product Labeling for the 
Technicon AutoAnaly2er II system. 
CAUTION! 
This reference material is processed from 
human plasma obtained from donors who 
have been tested for the absence of 
Australia antigen, using methods approved 
by, and reagents licensed by, the Bureau of 
Biologies, Food and Drug Administration. 
However, the possibility of contaminants 
cannot be excluded. HANDLE AS YOU 
WOULD ANY PATIENT SAMPLE. Do 
not piprtte by mouth. Avoid skin contact, 
and clean up spills immediately. 
Refer to the SMA Reference Serum 2 package insert for 
information concerning the DIRECTIONS FOR USE, 
STORAGE CONDITIONS. STABILITY, and ASSIGNED 
VALUES. 
CONTROLS 
(Refer to Table 3.) 
Technicon SCALE I (Low) (Serum Control for Automated 
Linearity Evaluation) and Technicon SCALE II (High) 
(Serum Control for Automated Linearity Evaluation) 
Composition of Technicon SCALE / and SCALE 11 
Controls. - Technicon SCALE. I (Low) and SCALE*"!! 
(High) serum controls for automated linearity evaluation 
are 1yophih?ed products that have been formulated as 
general purpose control materials for use in Technicon 
AutoAnalyzer II systems These controls ore prepared from 
defibnnated human plasma to which vaiious constituents 
have been added to achieve specific concentration levels. 
Added enzymes are derived from the following sources: 
LDH - bovine heart muscle, GOT — porcine heart muscle, 
alkaline phosphatase - chicken intestine, GPT - porcine 
heart muscle. Other additives are included to improve and 
preserve the characteristics of the product. 
A complete description of Technicon SCALE I and 
SCALE II controls together with suggested orocetfutes tor 
confirming their constituent concentration! are provided in 
Technical Bulletin No. TT4-0302-10. A copy of th*s 
bulletin is provided in VOLUME III of the Product 
Labeling for the Technicon AutoAnalyzer ii system. 
CAUTION! 
Technicon SCALE controls are processed from 
human plasma obtained from donors who have 
been tested for the absence of Au^alia 
antigen, using methods approved hv, and 
reagents licensed by. the Bureau wt Biologies, 
Food and Drug Administration. However, 
the possibility of contaminants cannot oe 
excluded. HANDLE AS YOU WO'lLD ANY 
PATIENT SAMPLE. Do not pippf* by mouth. 
Avoid skin contact, and clean up spills 
immediately. 
Refer to the appropriate Technicon SCALE control 
package insert for information concerning the 
DIRECTIONS FOR USE, S70RAGE CONDITIONS, 
STABILITY, and ASSIGNED VALUES. 
SYSTEM PERFORMANCE SPECIFICATIONS 
The following specifications apply to the glucose 
(glucoseoxidase) method as performed on Technicon 
AutoAnalyzer II systems: 
Rate of analysis - 60 samples/h 
Sample-to wash ratio - 9: t 
Chart speed - 1 inch/minute 
Linearity range - 0-500 mg/dl 
Sensitivity coefficient — 0.0009 absorban^e (£) unit per 
unit of concentration 
Minimum sample required - 9iil (approx) 
PATIENT PREPARATION 
Patients should be prepared according to the protocol 
established by the user's laboratory. 
SAMPLE COLLECTION AND PREPARATION 
Glucose should be assayed using clear, nonhemolyzed sera. 
The blood sample should be collected in commercially 
PART NUMBER PRODUCT NAME UNIT OF SALE 
T03 BGI0 CO SCALE I (Low) (serum control for automated 
lineanty evaluation and SCALE I Diluent 10 sets x 10 ml 
T03 8710-00 SCALE II (High) (scrum control for automated 
linearity evaluation) and SCALE II Diluent 10 sets x 10 ml 
T85 BS10-70 SCALE I (Low) (serum control for automated 
linearity evaluation) and SCALE I Diluent; 
SCALE II (High) (serum control for automated 
linearity evaluation) and SCALE II Diluent 
Package of 20 
sets x 10 ml 
Table 3 AVAILABLE TECHNICON SCALE CONTROL PRODUCTS 
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available collection tubes using routine venipuncture 
techniques and should be centrifuged at a speed of 2 700 
rev/min (RPM) for 10 to 12 min. Following centrifugation, 
the serum should be carefully decanted to avoid 
introducing clots into the system. Decant the serum 
directly into a (ample cup. 
The use of the Technicon SeraClear filtering device assures 
the preparation of clot-free serum samples. To ensure 
optimum performance when using the Technicon SeraClear 
filtering device, perform the following procedure: 
1. After drawing the specimen from the patient, place the 
collection tube in an upright vertical position, and allow 
the specimen to stand undisturbed for a period of about 
30 minutes prior to centrifugation. 
2. Before placing the specimen in the centrifuge, carefully 
rim the collection tube to free the clot from the glass. 
Perform this procedure carefully so that the cells are not 
hemolyzed. 
3. Ceniriluge the specimen at a speed of 2 700 rev/min 
(RPM) for 10 to 12 minutes. 
4. Slowly insert the SeraClear filtering device into the 
mouth of the collection tube. During insertion, make 
certain to keep the filtering device straight and parallel 
to the long axis of the collection tube. If the SeraClear 
filtering device is not inserted in this manner, the wiper 
may be bent; thereby, rendering the filter ineffective. 
5. Piess the filtering device into the collection tube unt'l 
the bottom of the filter'is positioned approximately 
1/2 mm above the packed red cells. If the SeraClc.n 
filtering device is pushed past the point specified, the 
cells may be disturbed; thereby, permitting them to pass 
through the filter. 
6. If the Sampler is equipped with the direct sampling 
capability, place the collection tubes on the Sampler, 
and allow the Sampler to aspirate sample directly from 
the collection tube. If the Sampler is not equipped fo» 
direct sampling, pour the filtered serum out of the 
SeraClear filtering device and into a sample cup. The 
sample is then aspirated from the sample cup. 
SAMPLE STABILITY 
When stored at 5 °C, serum samples are stable from 2 to 3 
days. 
SAMPLE DILUTION 
Serum samples with glucose concentrations greater than 
500 mg/dl should be diluted with distilled water or saline 
(0.9% NaCl) and reai&ayed. 
OPERATION 
Preoperation Procedure 
1. Verify that the interference filters are in the place in the 
Colorimeter and that both apertures are wide open 
(controls fully clockwise and down). Verify that the 
reversing switch is set to position D. Adjust the 
BASELINE control to midposition (5 turns from either 
limit). 
2. Set the proportioning pump POWER switch to position 
ON and the recorder SYSTEM switch to position 1 & 2. 
Press the colorimeter POWER ON push-button switch. 
3. Press the modular digital printer POWER ON 
push button switch. Verify that all modular digital 
printer lamps except the POWER ON and WASH lamps 
are off; then press the applicable CHAN ON push-button 
switch. 
4. Set the following modular digital printer controls to the 
position indicated: 
POSITION FOR 
60SAMPLErt> 
CONTROL OPERATION 
SAMPLING RATE switch 60 
WASH TIME switch 6 
MODE switch NORMAL 
RANGE switch 1000 
DECIMAL switch 000. 
TEST IDENT. control 36 
SAMPLE No. switches 000" 
5. On systems not equipped with the Modular Digital 
Printer, install the 60 Hr 9:1 sampler timing cam on the 
sampler timing motor shaft. 
6. install the proportioning pump cover plate and platen 
assembly. 
7. Connect each reagent line in accordance with Figure 1. 
Allow the system to warm up for ten minutes with 
reagents flowing and the sample probe in the wash 
reservoir. Check for proper bubble pattern. 
8. Set the recorder CHART DRIVE switch to position ON. 
9. Turn the colorimeter Rotary Display Switch to position 
ZERO. Adjust the ZERO control (screwdriver 
adjustment), if necessary, to position the recorder pen at 
2ero on the recorder chart paper. 
10. Turn the modular digital printer DISPLAY switch to the 
appropriate channel, and adjust the applicable ZERO 
control until the CONCENTRATION indicator displays 
000. 
11. Turn the colorimeter Rotary Display Switch to position 
FULL SCALE. Adjust the FULL SCALE control 
(screwdriver adjustment), if necessary, until the recorder 
pen is positioned at 100 (full scale) on the recorder chart 
paper. 
12. Adjust the appropriate modular digital printer CAL 
control until the CONCENTRATION indicator displays 
1000. 
13. Turn the colorimeter Rotary Display Switch to position 
NORMAL 
14. Adjust the colorimeter B (reference) Aperture until the 
modular digital printer CONCENTRATION indicator 
displays 000. Use the colorimeter BASELINE control 
for fine adjustment of the CONCENTRATION indicator 
display. 
Th*»e iwnche! c«r*b« M l  to ony numa»ical petition that may b« 
required to conform to Individual laboratory umpli handling and 
•ccounting proctdu'tt 
On sy items not equipped with a Modular Digital 
Printer, adjust the colorimeter B {reference) Aperture 
until the recorder pen is positioned at zero on the 
recorde; chart paper. Use the colorimeter BASELINE 
control for fine adjustment of recorder pen position. 
15. Set the recorder CHART DRIVE switch to position 
OFF. 
16. Turn the applicable modular digital printer RANGE 
switch to position 500. 
Daily Calibration and Operating Procedure 
1. Refer to and perform the preoperation procedure 
described in the preceding paragraph. 
2. Remove the sample tray covef. 
3. Load the sample tray in accordance with the following 
protocol; 
SAMPLE 
POSITION SAMPLE 
1.2 SMA Reft'iencu Serum 2 
3 14 Patient sampler 
15 SMA Reference Serum 7, SCALE I 
control, Of SCALE II control 
16-29 Patient samples 
30 SMA Reference Serum 2, SCALE I 
control, or SCALE M control 
3V40 Patient sjrnples 
| NOTE 
It is recommended thai Techmcon SCALE I 
and SCALE II controls be interspersed 
randomly among the patient samples The 
use of these controls provide additional 
quality contt ul Uu'i ks dut tug tin' p'orevstiuj 
of each sample u»ry. 
4. Install the end of run pin adjacent to the last sample. 
5. Replace the sample tray cover. 
6. Press to light the sampler POWER push button switch, 
and observe thjt the sampler probe cycles out of the 
wash reservoir and into the sample cup; then proceed as 
applicable: 
Initial tray - Piess to light the modular digital 
printer SAMPLE HOLD 
push button switch to halt the 
sampling cycle with the sample 
probe in the sample cup. After two 
minutes, press the modular digit.il 
printer SAMPLE HOLD 
push button switch, and proceed to 
step 7. 
On systems not equipped with a 
Modular Digital Printer, press the 
sampler POWER push button 
switch to turn the sampler off, 
thereby halting the sampling cycle 
with the sample probe in the 
sample cup. After two minutes, 
press to light the sampler POWER 
push button switch, and proceed to 
step 7. 
Succeeding tray — Proceed to step 7. 
7. Press to light the sampler ALARM push-button switch. 
8. Set the Recorder Chart Drive switch to position ON. 
9. Adjust the colorimeter BASELINE control until the 
modular digital printer CONCENTRATION indicator 
displays 000. 
On s/stems not equipped with a Modular Digital 
Printer, adjust the colorimeter BASELINE control until 
the recorder pen is positioned at zero on the recorder 
chart paper. 
10. As the first SMA Reference Serum 2 sample reaches 
steady state, adjust the colorimeter STD CAL control 
until the modular digital printer CONCENTRATION 
indicator displays a value equal to the glucose 
fglucose-oxidase) assay value specified on the SMA 
Reference Scrum 2 package insert. Observe the 
CONCENTRATIOfJ indicator during the ateady-state 
portion of the glucose curve and, when the nurrtbers 
displayed on the CONCENTRATION indicator start to 
decrease, press the applicable modular digital printer 
START PRINT push button switch. Immediately press 
and hold the applicable ADV PRINT push-button switch 
until the light in the push button flashes three (3) times. 
If the system is not equipped with a Modular Digital 
Printer, observe the steady-state portion of the curve 
produced by the first SMA Reference Serum 2 sample, 
and adjust the colorimeter STD CAL control until the 
recorder pen is positioned to the level on the recorder 
chart paper which corresponds to the glucose 
((jIuconp oxidase) assay value specified on the SMA 
Rek'ivnce Sv«um 2 packayc insert (each chart tecoidei 
unit = 5 mg/dl glucose). 
11. As the second SMA Reference Scrum 2 sample reaches 
steady state, the modular digital printer 
CONCENT RATION indicator should display the glucose 
(glucosc-oxidase) assay value. Adjust the colorimeter 
STD CAL control to correct for any discrepancy that 
may exist between the value displayed on the modular 
digital printer CONCENTRATION indicator and the 
value specified on the SMA Reference Serum 2 package 
insert. 
A short, sharp deflection of the pen will appear on 
the recorder trace when the Modular Digital Printer 
prints. Verify that this pen deflection occurs near the 
end of the steady-state plateau. Adjustment of the print 
liming may be made by pressing the appropriate ADV 
PRINT or RET PRINT push button. (Eoch flash 
represents a change of one second. The chart speed of 
the Recorder is 1/60 of an inch per second.) 
If the system is not equipped with a Modular Digital 
Printer, observe the steady-state portion of the curve 
produced by the second SMA Reference Serum 2 sample 
— the recorder pen should be positioned at a level which 
corresponds to the glucose (glucose-oxidase) assay value 
specified on the SMA Reference Serum 2 package insert 
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(each chart recorder unit s 5 mg/dl glucose). If the pen 
is not tracing along the level which corresponds to the 
assay value, adjust the Colorimeter STD CAL control to 
position the pun lo the proper level. 
12. After all the samples have been recorded, set the 
recorder CHART DRIVE switch to position OFF. 
If the system is not equipped with a Modular Digital 
Printer, convert the data recorded on the recorder chart 
paper into concentration units by multiplying the chart 
recorder units by 5 mg/dl glucose (glucose-oxidase), 
Shutdown Procedure 
1. Turn off all the modules except the Proportioning 
Pump. 
2 Place the reagent lines into a container of distilled water. 
3. Wash out the system with distilled water for 20 minutes. 
NOTE 
performed on a periodic basis or whenever the linearity of 
the method is in doubt. To perform the routine linearity 
check, proceed as follows: 
1. Refer to and perform the preoperation procedure 
previously described in this method. 
2. Remove the sample tray cover, and load the sample troy 
in accordance with the following protocol: 
SAMPLE 
POSITION 
1-3 
4,5 
6,7 
8.9 
SAMPLE 
SMA Reference Serum 2 
SCALE I control 
SMA Reference Serum 2 
SCALE II control 
After every other day ol operation, wash out 
* the MBTH/DMA and the peroxidase working 
reagent lines and pump tubes for 10 
minutes, using a 1 N solution of HCI. 
Following this wash, rinse out the lines and 
pump tul>cs for 10 minutes with distilled 
water. NEVER use a hypochlorite 
(Chlorox*) solution to wash out the glucose 
oxidase analytical cartridge or any of the 
rleated lines or pump tubes Washing out this 
channel with hypochlorite will produce 
erroneous results 
4. Remove the reagent lines from the container of distilled 
water. 
5. Remove the sample probe from the sample probe arm, 
and operate the AutoAnalyzer II system to pump aw 
through all lines until the system is completely dry. 
6. Replace the sample probe in the sample probe arm. 
7. Release and remove the proportioning pump cover plate 
and platen assembly. Set the proportioning pump 
POWER switch to position OFF. 
8. Change the dialyzer membrane weekly. An old 
membrane can cause low results. Before changing the 
membrane, wash out the sample. 0.9% sodium chloride, 
and glucose oxidase (working) reagent lines and pump 
tubes for 20 minutes using a 1 N solution of NaOH. 
Following this wash, rinse the lines and pump tubes for 
10 minutes with distilled water. Upon completion of this 
washout procedure, proceed to change the membrane. 
9. The glucose color reagent (MBTH/DMA) line should be 
changed every six weeks. The line becomes very 
discolored with time. The shoulders on the 
quick-disconnect mechanism also should be changed 
regularly. 
METHOD PERFORMANCE CHECKS 
Routine Linearity Check 
The routine linearity check is a convenient means for 
monitoring method linearity. This check should be 
3. Replace the sample tray cover. 
4. Press to light the sampler POWER push-button switch. 
5. Set the recorder CHART DRIVE switch to position ON. 
6. Adjust the colorimeter BASELINE control to position 
the recorder pen at 2ero on the recorder chart p»iper. 
7. As the first SMA Reference Serum 2 tample reaches 
steady state, adjust the colorimeter STD CAL control 
until the modular digital printer CONCENTRATION 
indicator displays a value equal to the glucose 
(glucose-oxidase) assay value specified on the SMA 
Reference Serum 2 package insert. 
On systems not equipped with a Modular Digital 
Printer, adjust the colorimeter STD CAL control to 
position the recorder pen to the level on the recorder 
chart paper which corresponds to the glucose 
(glucose-oxidase) assay value specified on the SMA 
Reference Serum 2 package insert (each chart recorder 
unit * 5 mg/dl glucose). 
8. Identify each sample as its curve is traced on the 
recorder chart paper. 
9. After all the samples have been recorded, set the 
recorder CHART DRIVE switch to position OFF. 
10. Refer to the appropriate package insert to obtain the 
glucose (glucose-oxidase) concentration in each sample. 
11. Using linear graph paper, plot the modular digital printer 
units vs glucose concentration. A typical routine 
linearity curve is illustrated in Figure 2. 
On systems not equipped with a modular digital 
printer, use linear graph paper to plot the recorder chart 
units vs glucose concentration. (See Figure 2.) 
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Conditional Linearity Check 
The conditional linearity check provides a rigorous 
assessment of method linearity. This check should be 
performed after changing reagent lot numbers, pump tubes, 
flowcells. colorimeters, etc. To perform the conditional 
linearity check proceed as follows: 
1. Refer to and perform the preoperation procedure 
previously described in this method. 
2. Remove the sample tray cover, and load the sample tray 
in accordance with the following protocol: 
SAMPLE 
POSITION SAMPLE 
1-3 SMA Reference Serum 2 
4 100 mg/dl glucose standard 
5 200 mg/dl glucose standard 
6 300 mg/dl glucose standard 
7 400 mg/dl glucose standard 
8 500 mg/dl glucose standard 
I NOTE I 
The glucose concentrations specified are 
approximate. 
It is recommended that dilutions of retained 
patients' sera be used. However, NBS 
standards or dilutions of commercial 
standards also are acceptable. 
3. Replace the sample tray cover. 
4. Press to light the sample POWER push-button switch. 
5. Set the recorder CHART DRIVE switch to position ON. 
6. Adjust the colonmetei BASELINE control to position 
the recorder pen at zero on the recorder chart paper. 
7. As the first SMA Reference Serum 2 sample reaches 
steady state, adjust the colorimeter STD CAL control 
until the modular digital printer CONCENTRATION 
indicator displays a value equal to the glucose 
(glucose-oxidase} assay value specified on the SMA 
Reference Serum 2 package insert. 
On systems not equipped with a Modular Digital 
Printer, adjust the colorimeter STD CAL control to 
position on the recorder pen to the level on the recorder 
chart paper which corresponds to the glucose 
(glucose-oxidase) assay value specified on the SMA 
Reference Serum 2 package insert (each chart recorder 
unit = 5 mg/dl glucose). 
8. Identify each sample as its curve is traced on the 
recorder chart paper. 
9. After all the samples have been recorded, set the 
recorder CHART DRIVE switch to position OFF. 
10. Using linear graph paper, plot the modular digital printer 
units vs glucose concentration. A typical conditional 
linearity curve is illustrated in Figure 3. 
On systems not equipped with a Modular Digital 
Printer, use linear graph paper to plot the recorder chart 
units vs glucose concentration. (See Figure 3.) 
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Reagent vs Water Absorbance Check 
The reagent vs water absorbance check is performed to 
evaluate overall system performance. System optics, 
hydraulics, and reagents are involved in the performance of 
this check. A malfunction in any of these items can 
contribute to a poor reagent absorbance. To perform the 
reagent vs water absorbance check, proceed as follows: 
1. Start the Proportioning Pump, and place all reagent lines 
into a container of distilled water. After water has 
reached flowcetl (approximately 10 minutes), check for 
proper bubble pattern. 
2. Adjust the colorimeter STD CAL control to 100, 
3. Set the recorder CHART DRIVE switch to position ON. 
4. Turn the colorimeter Rotary Display Switch to position 
ZERO and, using a screwdriver, adjust the ZERO con­
trol to position the recorder pen at zero on the recorder 
chart paper. 
5. Turn the Rotary Display Switch to position FULL 
SCALE and, using a screwdriver, adjust FULL SCALE 
control to position the recorder pen at 100 (full scale) 
on the recorder chart paper. 
6. Turn the Rotary Display Switch to position NORMAL, 
and adjust the colorimeter Reference Aperture to 
position the recorder pen at zero on the recorder chart 
paper. Fine control of this adjustment is obtained by 
using the colorimeter BASLEINE control. 
7. Remove the reagent lines from the container of distilled 
water, and connect them to their respective reagent 
container (see Figure 1). After ten minutes, check for 
proper bubble pattern. 
8. Record the absorbance (£) units as calculated from the 
values indicated on the recorder chart paper (10 chart 
recorder units equal 0.1 absorbance [E] unit). The 
approximate reagent absorbance for the glucose 
(glucose-oxidase) method is 0.03 E. Minor variations in 
reagents, pump tubes, f lowcells, etc. can cause deviations 
from the specified value; therefore, an acceptable range 
for each system should be determined over a period of 
time. 
100 
I NOTE I 
Maintain a permanent record of the recorded 
absorbances — this record will be a valuable 
troubleshooting aid. 
Sensitivity Check 
The sensitivity check is a procedure that is performed to 
monitor the overall performance of the glucose 
(glucose-oxidase) method. To perform the sensitivity check 
OP the Technicon AutoAnalyzer II system, proceed as 
follows: 
1. Refer to and perform the preoperation procedure 
previously described in this method. 
2. Adjust the colorimeter STD CAL contfol to 100. 
3. Remove the sample tray cover. 
4. Place a sample cup of SMA Reference Scrum 2 in the 
first sample position on the sample tray 
5. Replace the sample tray cover. 
6. Press to light the sampler POWER ON push button 
switch, 
7. Set the recorder CHART DRIVE switch to position ON. 
8. Record the absorbance (£) units as calculated from the 
value recorded on the recorder chart paper for the SMA 
Reference Serum ? sample (10 char l recorder units - 0.1 
absorbance |£| units). Obtain (from the SMA Reference 
Serum ? package insert) the glucose (glucose-oxidase) 
assay value. 
9. Set the recorder CHART DRIVE switch to position 
OFF. 
10. Calculate the sensitivity coefficient by dividing the 
absorbance [B) units recorded in step 8 by the glucose 
fgiucost -oxidase) assay value spri ifu.'il on the SMA 
Reference Seium ? package insnl. The approximate 
glucose sensitivity coefficient is 0.0009 absorbance (£) 
unit per unit of concentration. Minor variations in 
reagents, pump tubes, flowcelts. etc. can cause 
deviations fiom the specified sensitivity values, 
therefore, and acceptable range for each system should 
be determined over a period of time. 
| NOTE | 
Maintain a permanent record of sensitivity 
values - this record will be a valuable 
troubleshooting aid. 
RESULTS 
Range of Expected Values 
The range of expected values for the glucose 
(glucose-oxidase) method, as performed on the Technicon 
AutoAnalyzer II system, is 70 to 100 mg'dl. 
Calculation of Results 
On the Technicon AutoAnalyzer II system, the test results 
for each sample is printed in direct concentration units. If 
the system is operated without the Modular Digital Printer, 
convert the recorder units into concentration units of 
glucose by multiplying the chart recorder units by 5 mg/dl. 
Interfering Substances 
A number of substances have been reported to cause 
physiological changes in glucose concentration. ,0J1,12 A 
comprehensive discussion of these substances, their serum 
concentrations, and their possible physiological involve­
ments is beyond the scope of this Product Labeling. How­
ever, the following substances, if present In the sample, 
reagents, or system, may interfere in glucose determina­
tions in the manner described: 
Galactose - This substances may cause an elevation (5%) in 
the determination of glucose levels. 
Maltose - Maltose can cause a significant elevation (30%) in 
the determination of glucose levels. 
Diethreitol — This substance may cause an elevation (5%) in 
the determination of glucose levels. 
Hydrazine Sulfate - This substance may cause an elevation 
(5%) in the determination of glucose levels. 
Phunylhydrazine • HCI — This substance may inhibit the 
glucoseoxidase method, resulting in a significant 
depression (65%) of glucose levels determined by this 
method. 
Ascorbic Acid — Ascorbic acid may inhibit the 
glucose oxidase method, resulting in a depression (10' u) 
of glucose levels determined by this method. 
A study performed by Carey, Feldbruegge, and Westgard13 
reported that the glucose oxidase (MBTH-DMA) method 
was not significantly affected by uric acid levels of 25 mg/dl 
or less. 
Interpretation of Results 
System operators and laboratory supervisors have a 
responsibility to determine that the Technicon 
AutoAnalyzer It system is performing accordtng 
to specification and that the maintenance and trouble­
shooting procedures outlined in VOLUME I of this 
Product Labeling are followed. In the event of a grossly 
aberrant result, as defined by the laboratory protocol, 
a determination should first be made that the system is 
performing correctly. The operator then should follow 
the laboratory's predetermined protocol for advising the 
clinician of a result which has deviated from the 
established norm. 
Technicon adequately identifies potential aberrant results 
based on machine function (or reagent function) through 
the Troubleshooting and Maintenance sections contained in 
VOLUME I of this Product Labeling. Technicon con­
siders these sections of the Product Labeling to be 
responsive to the question of how to handle an apparent 
abnormal result. This troubleshooting and maintenance 
information is provided in lieu of attempting to assume a 
responsibility that may involve medical judgement. 
The interpretation of results and determinations concerning 
a need for further testing involve decisions which are best 
made by the clinician who has the most complete physical 
and clinical picture of the patient's condition. 
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METHOD PERFORMANCE CHARACTERISTICS 
Within-run Precision Study 
The within-run precision of the glucose (glucose-oxidase) 
method was studied using dilutions of a spiked pool of 
Techr.'con SMA Reference Serum as test samples. Each test 
sample w^s assayed a minimum of 24 times, consecutively. 
The results obtained from this study are provided in 
Table 4. 
Table 4 WITHIN-RUN PRECISION STUDY 
TEST 
SAMPLE 
1 
TEST 
SAMPLE 
2 
TEST 
SAMPLE 
3 
Number of Assays 36 24 24 
Mean (mg/dl) 97 194 388 
Coefficient of 
Variation {%) 0.66 0.47 0.87 
Standard Deviation 0.84 0.92 3.39 
Correlation Studies 
Technicon SMA 12/60 System vs Manual Hexokinase 
Method 
The pi-rformance of the glucose (glucoseoxidasc) method 
was independently compared to a manual hexokinase 
method by Carey. Feldbruegge, and Westgnrd 13 The study 
was performed using a Technicon 12/60 system. However, 
the results obtained apply equally io the Technicon Auto 
Analyzer II system, since both systems perform glucose 
(glucose oxidase) determinations by the same method. As 
shown in Figure 4, tho results of the study indicate a smjll 
bias of 2.05 mg/dl between the two methods. 
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Figure 4 CORRELATION STUDY - TECHNICON 
SMA 12/60 SYSTEM VS MANUAL 
HEXOKINASE METHOD 
Technicon SMA 12/60 System vs Automated o• Toluidine 
Method 
The performance of the glucoM? (glucose-oxidatc) method 
was independently compared to an automated o-toluidine 
method by Carey, Feldbiuegge. and Westgard.13 The study 
was performed using a Technicon 12/60 syitem. However, 
the results obtained apply equally to the Technicon Auto-
Analyzer fl system, since both systems perform glucose 
(glucoseoxidase) determinations by the same method. As 
shown in Figure 5, the results of the study indicate that 
there is no significant bias between the two methods. 
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Figure 5 CORRELATION STUDY - TECHNICON 
SMA 12/60 SYSTEM VS AUTOMATED 
o-TOLUIDINE METHOD 
Technicon AutoAnatyier If System vs Technicon SMA 
12/60 System (Glucose-Oxidasel 
The performance of the glucose (glucose-oxidase) method 
was compared to the glucose (glucose oxidase) method as 
performed on the Technicon SMA 12/60 system. A sample 
population of 998 random patients' sera was analyzed 
consecutively by both systems. The results obtained from 
this study are provided in Table 5. 
Table 5 CORRELATION STUDY - TECHNICON 
AUTOANALYZER II SYSTEM VS TECHNICON 
SMA 12/60 SYSTEM (GLUCOSE-OXIDASE) 
TECHNICON TECHNICON 
AUTOANALYZER II SMA 12/60 
SYSTEM SYSTEM 
(GLUCOSE- (GLUCOSE 
OXIDASE) OXIDASE 
(x-axn) 
Number of Samples 
Mean (mg/dl) 
Standard Deviation 
of Sample 
Population 
Correlation 
Coefficient 
Slope of 
Regression Line 
^•Intercept 
0.99B 
0.976 
N - 371 
V - 1.004 X • 1.57 
SO- 3.11 rr»o/ril 
BIAS — 2.05 mg/dl 
0 100 200 300 400 500 
MANUAL HEXOKINASE METHOD 
N - 1020 
Y - 1.016 X - 1.73 
SD — 4.59 mg/dl 
BIAS — < 0.1 mg/dl 
0 100 200 300 400 500 
AUTOMATED o-TOLUIDINE METHOO 
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These statistical data demonstrate a positive correlation 
between the results obtained from both systems. The 
correlation study indicates that there is no significant 
difference in the values obtained from the sample 
population as assayed on the Technicon AutoAnalyzer II 
and SMA 12/60 systems. 
Technicon AutoAnalyzer If Systems— Glucose-Oxidase 
vs Neocuproine 
The performance of the glucose-oxidase method was 
compared to the neocuproine method. A sample population 
of 103 random patients' sera was analyzed consecutively by 
both methods. As shown in Table 6, a small bias was found 
to exist between the two methods, with the glucose-oxidase 
method giving 5% lower values than the neosuproine method 
for the sample population. 
Recovery Study 
The ability to recover precisely known levels of glucose was 
studied using dilutions of Technicon SMA Reference 
Serum. One set of the test samples was spiked with a 
specific level of a glucose standard. The second set was used 
as a control. The percentage of glucose concentration 
recovered, at each test level, was calculated using the 
following formula: 
Value of Test Sample (Spiked) - Value of Test Sample (Control) 
% Recovery s — — ~—• X 100 
Value of Spike 
to adhere strictly to the maintenance recommendations 
prescribed in VOLUME I of the Product Labeling for the 
Technicon AutoAnalyzer II system. 
Protein Effect on Dialysis 
Experimental evidence has indicated that there is no 
clinically significant protein effect on dialysis throughout 
the entire range of the glucose (glucose-oxidase) method. 
At no time do varying levels of protein concentration 
decrease test results by more than 5%, not even in the 
extreme, seldom encountered case of high protein and high 
sample concentrations. 
The quantitative effect of protein on dialysis is directly 
related to the operating condition of the system. The 
system should be kept clean and the dialyzer membrane 
should be inspected and changed in accordance with the 
maintenance recommendations specified In VOLUME I of 
the Product Labeling for the Technicon AutoAnalyzer II 
system. 
TROUBLESHOOTING 
Troubleshooting should take the path of feast resistance 
and the path of least effort on the part of the operator. 
Always look for the most obvious and for the most easily 
repaired source of trouble. When troubleshooting the 
glucose (glucose-oxidase) method, the first step is to 
localize the trouble. In the continuous-flow method of 
analysis, the bubble is an important part of the system 
operation. Although a number of factors contribute to an 
Table 6 GLUCOSE-OXIDASE vs NEOCUPROINE 
TECHNICON 
AUTOANALYZER II 
SYSTEM 
GLUCOSE-OXIDASE) 
<K*oxii) 
TECHNICON 
AUTOANALYZER II 
SYSTEM 
(NEOCUPROINE) 
(x-axis) 
Number of Samples 103 103 
Mean (mg/dl) 110 116 
' Standard Deviation 
of Standard 
Population | 60.4 54.3 | 
Correlation 1 1 
Coefficient 0.686 
Slope of 
Regression Line 1.11 
K-lntercept -19.3 
The results obtained from this study are listed in Table 7. 
Table 7 RECOVERY STUDY 
DILUTION 
OF TECHNICON PERCENT OF 
REFERENCE CONCENTRATION GLUCOSE 
SERUM OF GLUCOSE CONCENTRATION 
(XI (mg/dl) RECOVERED 
25 60 100 
50 125 99.5 
100 247 97.5 
Sample Interaction Study 
Experimental evidence indicates that within the range of 
expected values for the glucose (glucose-oxidase) method, 
the amount of sample interaction (carryover) is not 
clinically significant (less than 5%). In the extreme case, 
where a sample with an extremely high concentration, well 
beyond the expected range, is followed by a sample with a 
very low concentration, the amount of sample interaction 
may result in a clinically significant (greater than 5%) 
elevation of the concentration in the sample. In routine 
clinical use, this situation is seldom encountered. 
The quantitative effect of carryover at any concentration 
level is directly related to the operating condition of the 
system. Conditions such as worn pump tubes, diry 
flowceils, clogged dialyzer membranes, etc. can have a 
deleterious effect on results. Accordingly, the user is urged 
14 
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improper bubble pattern, it is always the easiest feature of 
system operation to check, since the tubing is transparent 
and most of the pathways are exposed. 
For troubleshooting purposes, note the following 
information for the glucose (glucose oxidase) method as 
performed on the Technicon AutoAnalyzer II 
continuous-flow analytical instrument; 
' 1. SMA Reference Smim {250 mg/dl glucose) Absorbance 
- 0.225 B (appiox) 
Full Scale (500 mg/dl glucose) Absorbance - 0.450 E 
(appiox) 
3. Reagent vs Water Absorbance - 0.03 E (appiox) 
J MOTE | 
The absorbances (£") specified ace 
approximate. Minor variations in reagents, 
pump tubes, flowcells, etc. can cause 
deviations from the specified values. An 
acceptable range for each system should 
be determined over e period of tirne. 
Table 8 provides a fist of possible troubles that could be 
encountered while running the glucose (glucose-oxidase) 
method. The Table also lists the probabcl cause of each 
difficulty and the suggested corrective maintenance 
procedures. 
Table 8 TROUBLESHOOTING 
TROUBLE PROBABLE CAUSE CORRECTIVE MAINTENANCE 
Au bubbles in system: 
Sudden deflection of 
recorder pen from 
bascMne 
Micro air bubbles passing through 
f iovvccll 
Check for air leakage into the 
system, and for constrictions 
in the flow path. 
Slou drceast* in 
it*coi(lei pi*n |>t>*»11ion 
from baseline 
Excessive air in dialy/er 
donor stream 
Check size of pump tubes associated 
with donor stream. Check for con­
striction in the flow path. 
Random NOISE Reaiji-nts dirty Filter the reagents through filter 
paper. 
Chatter noise Dirt on slidewire of recorder Clean the shdewire. 
Pooi sensitivity 01 
IMK'JI I t y 
Delrclive reagents Inspect each reagent used with 
this method. Replace or prepare 
fresh reagent, as applicable. 
Detective dialyzer membrane Replace dialy2er membrane 
Worn pump tubes Replace pump tubes, as required. 
No reaction Reagent lines connected to 
mamtold incorrectly 
Refer to the flow diagram, 
Figure 1, for correct reagent 
line connections. 
Foi a compiehenbivc lt>i of irbtcd publications which provide additional troubleshooting information, refer to 
VOLUME III of iht.' Product Label.ng for ihi> Technicon AutoAnalyzer II system. 
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APPENDIX D 
Fasting Plasma Total Cholesterol, High Density 
Lipoprotein Cholesterol, and Glucose 
Concentrations for Females 
and Males 
ID 
001 
003 
006 
009 
Oil  
024 
025 
027 
028 
030 
031 
106 
Females 
Fasting Plasma Glucose (mg%) 
0 4 8 12 
Pre Post  Pre Post  Pre Post  Pre Post  
107 126 
99 
90 
87 
95 106 
104 143 
88 128 
96 114 
89 124 
84 102 
86 127 
88 128 
97 
92 101 
90 
100 116 
88 145 
80 108 
93 133 
80 120 
96 127 
88 135 
91 
93 116 
92 
99 122 
76 131 
77 118 
106 152 
84 122 
88 130 
94 
89 105 
99 
93 138 
75 141 
71 91 
94 147 
68 115 
87 112 
86 139 
Males 
Fasting Plasma Glucose (mg%) 
Week 0  4 8 12 
Exercise  Pre Post  Pre Post  Pre Post  Pre Post  
ID 
802 101 100 101 97 103 103 100 98 
803 112 132 103 132 105 124 102 145 
804 95 132 101 150 98 146 104 162 
805 104 198 104 143 115 167 122 157 
806 94 84 98 119 101 120 103 136 
807 97 89 96 92 91 99 96 100 
820 99 — 95 143 92 135 91 135 
821 98 113 96 122 97 119 96 123 
822 96 115 91 115 87 131 87 131 
825 105 117 77 103 110 84 89 
ID 
001 
003 
006 
009 
Oil  
024 
025 
027 
028 
030 
031 
108 
Females 
Fasting Plasma Total Cholesterol (mg%) 
0 4 8 12 
Pre Post  Pre Post  Pre Post  Pre Post  
1 6 1  
88 
214 
196 
200 
175 
173 
182 
190 
308 
228 
237 
207 
178 
205 
199 
302 
209 
157 
141 
153 
178 
135 
170 
131 
214 
234 
298 
202 
175 
158 
200 
158 
135 
223 
223 
271 
199 
118 
172 
224 
204 
174 
198 
211 
184 
196 
308 
159 
230 
233 
178 
192 
153 
201 
209 
292 
177 
166 
178 
189 
266 
186 
235 
230 
265 
182 
156 
182 
194 
260 
172 
Wee 
cerc 
ID 
802 
803 
804 
805 
806 
807 
820 
821 
822 
825 
109 
Males 
Fasting Plasma Total Cholesterol (mg%) 
0 4 8 12 
Pre Post  Pre Post  Pre Post  Pre Post  
140 
202 
141 
196 
239 
254 
151 
132 
186 
149 
225 
227 
141 
217 
239 
209 
174 
223 
201 
163 
228 
116 
236 
218 
203 
165 
178 
213 
138 
165 
205 
145 
236 
208 
219 
178 
235 
176 
168 
239 
177 
225 
252 
234 
150 
168 
197 
147 
247 
303 
204 
155 
225 
287 
194 
186 
218 
158 
287 
215 
139 
253 
200 
219 
155 
175 
176 
159 
249 
191 
192 
259 
173 
269 
160 
181 
213 
161 
ID 
001 
003 
006 
009 
Oil  
024 
025 
027 
028 
030 
031 
110 
Females 
Fasting Plasma HDL-Cholesterol (mg%) 
0 4 8 12 
Pre Post  Pre Post  Pre Post  Pre Post  
34 23 44 44 — 47 46 
48 55 47 27 54 44 31 
47 — 39 41 61 34 42 54 
21 — 28 — 34 — 43 — 
45 — 44 51 43 45 56 49 
45 54 59 42 45 48 43 53 
48 58 46 50 78 78 55 52 
85 64 83 86' 70 81 74 — 
65 — 54 — — — 55 — 
37 46 36 31 _ _  60 44 
Ill 
Males 
Fasting Plasma HDL-Cholesterol (mg%) 
Week 0  4 8 12 
Exercise  Pre Post  Pre Post  Pre Post  Pre Post  
ID 
802 
803 26 27 31 37 32 32 25 30 
804 24 30 36 35 — 34 41 41 
805 38 42 — — 57 33 42 50 
806 46 59 34 47 — 34 46 38 
807 25 28 36 49 49 36 46 46 
820 43 — 40 34 40 43 23 33 
821 29 32 25 24 21 23 30 30 
822 30 40 47 50 47 46 30 39 
825 41 36 54 — 48 53 50 55 
112 
Females 
HDL-Cholesterol:Total Cholesterol 
Week 0  4 8 12 
Exercise  Pre Post  Pre Post  Pre Post  Pre Post  
ID 
001 0 .21 0.11 0.28 0.28 — — 0.24 0.20 
003 0.55 — 0.33 — 0.46 — 0.29 — 
006 
DOQ 
0 .22 — 0.25 0.26 0.35 0.17 0.21 0.23 
\j\jy 
011 0.11 — 0.21 — 0.17 — 0.15 — 
024 0.26 — 0.26 0.32 0.25 0.28 0.32 0.27 
025 0.26 0.30 0.45 0.31 0.23 0.21 0.26 0.34 
027 0 .26 0.28 0.21 0.22 0.37 0.33 0.31 0.29 
028 0.45 0.32 0.35 0.39 0.38 0.46 0.39 — 
030 0.21 — 0.18 — — — 0.21 — 
031 0.16 0.22 0.18 0.16 0.32 0.26 
113 
Males 
HDL-Cholesterol:Total Cholesterol 
Week 0  4 8  12 
Exercise  Pre Post  Pre Post  Pre Post  Pre Post  
• ID 
802 — — 
803 0 .13 0.12 0.14 0.18 0.13 0.11 0.12 0.16 
804 0.17 0.21 0.31 0.24 — 0.17 0.29 0.21 
805 0 .19 0.19 — — 0.25 0.21 0.17 0.19 
806 0 .19 0.25 0.16 0.23 — 0.15 0.23 0.22 
807 0 .10 0.13 0.18 0.22 0.21 0.13 0.21 0.17 
820 0 .28 — 0.24 0.19 0.27 0.22 0.15 0.21 
821 0 .22 0.18 0.14 0.10 0.13 0.12 0.17 0.17 
822 0.16 0.18 0.22 0.28 0.24 0.21 0.17 0.18 
828 0.28 0.18 0.38 — — 0.32 0.34 0.31 0.34 
